

MISSISSIPPI DIVISION OF MEDICAID UNIVERSAL PREFERRED DRUG LIST

EFFECTIVE 7/01/2025
VERSION 2025_7
Updated 7/30/2025

General Preferred Drug List Information

- Gainwell Technologies DUR+ process is a proprietary electronic prior authorization system used for Medicaid pharmacy claims.
- Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
- PREFERRED BRANDS** will not count toward the two-brand monthly Rx Limit.
- Drugs highlighted in **yellow** denote change in PDL status.
- To search the PDL, **press CTRL + F**.

Medication Coverage Status Search Tool - [Pharmacy Drug Coverage Inquiry](#)

ACNE AGENTS

PREFERRED AGENTS

NON-PREFERRED AGENTS

PA CRITERIA

ANTI-INFECTIVES

Maximum Age Limit

- **21 years:** all acne agents except isotretinoin products

Topical Clindamycin 1% lotion

- **21 years** and older **AND**
- Documented diagnosis of hidradenitis suppurativa

clindamycin gel (generic CLEOCIN-T)	azelaic acid
clindamycin lotion, medicated swab, solution	CLEOCIN T (clindamycin)
	CLINDACIN (clindamycin)
	CLINDAGEL (clindamycin)
	clindamycin foam

	clindamycin gel (generic CLINDAGEL)
	dapsone
	ERY (erythromycin)
	ERYGEL (erythromycin)
	erythromycin
	EVOCLIN (clindamycin)
	KLARON (sulfacetamide)
	MORGIDOX (doxycycline)
	sulfacetamide sodium suspension
	WINLEVI (clascoterone) cream
ISOTRETINOIN PRODUCTS	
AMNESTEEM (isotretinoin)	ABSORBICA (isotretinoin)
CLARAVIS (isotretinoin)	isotretinoin
ZENATANE (isotretinoin)	
KERATOLYTICS (BENZOYL PEROXIDES)	
ACNE MEDICATION (benzoyl peroxide)	BPO towelette (benzoyl peroxide)
benzoyl peroxide	
LINTERA (benzoyl peroxide)	
RETINOIDS	
adapalene gel, gel with pump	adapalene cream
RETIN-A (tretinoin)	AKLIEF (trifarotene)
tretinoin cream	ALTRENO (tretinoin)
	ARAZLO (tazarotene)
	ATRALIN (tretinoin)
	DIFFERIN (adapalene)
	FABIOR (tazarotene)
	RETIN-A MICRO (tretinoin)
	RETIN-A MICRO PUMP (tretinoin)
	tretinoin gel
	tretinoin microsphere
OTHERS/COMBINATION PRODUCTS	
adapalene/benzoyl peroxide gel	ACANYA (benzoyl peroxide/clindamycin) gel
clindamycin/benzoyl peroxide 1%-5% gel w/pump	CABTREO (clindamycin/adapalene/benzoyl peroxide) gel
sodium sulfacetamide w/sulfur 8%-4%, 9%-4.25%, 10-5% suspension	CLEANSING WASH (sulfacetamide sodium/sulfur/urea) cleanser
	clindamycin phosphate/benzoyl peroxide 1.2%-2.5% gel
	clindamycin phosphate/tretinoin 1.2%-0.025% gel
	clindamycin/benzoyl peroxide 1%-5% gel
	clindamycin/benzoyl peroxide 1.2%-3.75% gel w/pump (generic ONEXTON)
	EPIDUO FORTE (adapalene/benzoyl peroxide) gel
	erythromycin/benzoyl peroxide gel
	NEUAC (benzoyl peroxide/clindamycin) cream, gel
	ONEXTON (benzoyl peroxide/clindamycin) gel
	sodium sulfacetamide w/sulfur 8%-4% cleanser
	sodium sulfacetamide w/sulfur 10%-2% cream
	sodium sulfacetamide w/sulfur 10%-5% cream, lotion
	SSS (sodium sulfacetamide/sulfur)10-5 cream, foam
	TWYNEO (benzoyl peroxide/tretinoin) cream
	ZIANA (clindamycin/tretinoin) gel
	ZMA CLEAR (sodium sulfacetamide/sulfur) suspension

Note:

Isotretinoin products available for all ages

Clindamycin 1% lotion only available for ages 21 years and older with approvable diagnosis

Preferred clindamycin 1% lotion for ages < 21 years does not require PA

ALPHA-1 PROTEINASE INHIBITORS

PREFERRED AGENTS		NON-PREFERRED AGENTS	PA CRITERIA		
ARALAST NP					
GLASSIA					
PROLASTIN C					
ZEMAIRA					
ALZHEIMER’S AGENTS ^{DUR+}					
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA			
CHOLINESTERASE INHIBITORS		Preferred Criteria - Documented approvable diagnosis Non-Preferred Criteria - Documented approvable diagnosis AND - Have tried 2 different preferred agents in the past 6 months NAMZARIC - Requires clinical review ZUNVEYL - Requires clinical review			
donepezil 5 mg, 10 mg ODT, tablets	ADLARITY (donepezil)				
galantamine	ARICEPT (donepezil)				
galantamine ER	donepezil 23 mg tablet				
rivastigmine	EXELON (rivastigmine)				
	Zunveyl (benzgalantamine gluconate) ^{NR}				
NMDA RECEPTOR ANTAGONISTS					
memantine	memantine ER				
	NAMENDA (memantine)				
	NAMENDA XR (memantine ER)				
COMBINATION AGENTS					
	NAMZARIC (memantine/donepezil)				
	memantine/donepezil ER				
ANALGESICS, OPIOID-SHORT ACTING ^{DUR+}					
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA			
acetaminophen/caffeine/dihydrocodeine	ACTIQ (fentanyl)	MS DOM Opioid Initiative Criteria details found here - Morphine Equivalent Daily Dose - Concomitant use of Opioids and Benzodiazepines Minimum Age Limit 18 years: codeine-containing products and tramadol-containing products Quantity Limit (per 31 rolling days) 62 tablets: butalbital/codeine combinations, codeine combinations, dihydrocodeine combinations, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, morphine, oxycodone, oxymorphone, pentazocine, tapentadol, tramadol 186 tablets: butalbital/acetaminophen, butalbital/aspirin 5 mL: butorphanol nasal 180 mL: oxycodone liquid 280 mL: QDOLO Non-Preferred Criteria - Have tried 2 different preferred agents in the past 6 months MS DOM Opioid Initiative Criteria details found here - Morphine Equivalent Daily Dose - Concomitant use of Opioids and Benzodiazepines Minimum Age Limit 18 years: BUTRANS and tramadol-containing products			
acetaminophen/codeine	aspirin/butalbital/caffeine/codeine				
codeine	butalbital/acetaminophen/caffeine/codeine				
ENDOCET (oxycodone/acetaminophen)	butorphanol				
hydrocodone/acetaminophen	DILAUDID (hydromorphone)				
hydromorphone	fentanyl citrate				
morphine sulfate	FENTORA (fentanyl)				
oxycodone	FIORICET W/CODEINE (butalbital/acetaminophen/codeine)				
oxycodone/acetaminophen (325 mg acetaminophen formulations)	hydrocodone/ibuprofen				
tramadol 50 mg tablet	meperidine				
tramadol/acetaminophen	NALOCET (oxycodone/acetaminophen)				
	levorphanol				
	oxymorphone				
	pentazocine/naloxone				
	PERCOCET (oxycodone/acetaminophen)				
	PROLATE (oxycodone/acetaminophen)				
	ROXICODONE (oxycodone)				
	ROXYBOND (oxycodone)				
	SEGLENTIS (tramadol/celecoxib)				
	tramadol 25 mg, 75 mg, 100 mg tablet				
	tramadol solution				
ANALGESICS, OPIOID-LONG ACTING ^{DUR+}					
PREFERRED AGENTS	NON-PREFERRED AGENTS			PA CRITERIA	
BUTRANS (buprenorphine)	BELBUCA (buprenorphine)			Quantity Limit (per 31 rolling days) 31 tablets: AVINZA, hydromorphone ER, HYSINGLA ER, tramadol ER 62 tablets: methadone, morphine ER, OXYCONTIN, oxymorphone ER, ZOHYDRO ER 62 films: BELBUCA 10 patches: fentanyl 4 patches: BUTRANS	
fentanyl patch	buprenorphine patch				
morphine sulfate ER tablet	CONZIP (tramadol)				
	hydrocodone bitartrate ER				
	hydromorphone ER				
	HYSINGLA ER (hydrocodone)				
	methadone				

	methadone intensol	Non-Preferred Criteria Have tried 2 preferred agents in the past 6 months
	METHADOSE (methadone)	
	morphine sulfate ER capsule	
	MS CONTIN (morphine)	
	oxycodone ER	
	OXYCONTIN (oxycodone)	
	oxymorphone ER	
	tramadol ER	

ANALGESICS/ANESTHETICS (TOPICAL)		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
diclofenac 1%, 3% gel	DERMACINRX LIDOCAN (lidocaine)	Quantity Limit (per 31 days) 1 bottle (112 mL): diclofenac 2% solution pump 1 bottle (150 mL): diclofenac 1.5% solution Non-Preferred Criteria - Have tried 2 preferred agents in the past 6 months Lidocaine 5% Patch - Documented diagnosis of Herpetic Neuralgia OR - Documented diagnosis of Diabetic Neuropathy ZTLIDO - Documented diagnosis of postherpetic neuralgia OR - History of 3 claims with preferred lidocaine 5% patch in the past 6 months
lidocaine 4% cream, patch, solution	DERMACINRX LIDOGEL (lidocaine)	
lidocaine 5% cream, ointment, patch	DERMACINRX LIDOREX (lidocaine)	
lidocaine 40 mg/mL solution	diclofenac epolamine	
lidocaine/prilocaine cream	diclofenac sodium 2% solution pump	
TRIDACAINE (lidocaine) patch	DICLOGEN (diclofenac/menthol/camphor) kit	
TRIDACAINE XL (lidocaine) patch	DOLOGESIC PAIN RELIEF (lidocaine)	
ULTRA LIDO (lidocaine) cream, gel	LIDAFLEX (lidocaine)	
	lidocaine 3% cream	
	lidocaine 4% kit, liquid	
	lidocaine/hydrocortisone	
	lidocaine/prilocaine kit	
	LIDOCAN II, III, IV, V (lidocaine)	
	LIDOCORT (lidocaine/hydrocortisone)	
	LIDODERM (lidocaine)	
	LIDOTRAL (lidocaine)	
	LIXOFEN (diclofenac)	
	PENNSAID (diclofenac)	
	PLIAGLIS (lidocaine/tetracaine)	
	TRIDACAINE II, III (lidocaine) patch	
	ZTLIDO (lidocaine)	

ANDROGENIC AGENTS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
testosterone	ANDROGEL (testosterone)	All Agents - Limited to male gender Non-Preferred Criteria - Have tried 2 different preferred agents in the past 6 months TLANDO - Requires clinical review
	JATENZO (testosterone undecanoate)	
	NATESTO (testosterone)	
	TESTIM (testosterone)	
	TLANDO (testosterone undecanoate)	
	VOGELXO (testosterone)	
	UNDECATREX (testosterone undecanoate)	

ANGIOTENSIN MODULATORS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS		EPANED - Automatic approval issued for 0-6 years of age ENTRESTO - Age ≥1 year and documented diagnosis of Heart Failure with Systemic Ventricular Systolic Dysfunction OR - Age ≥ 18 years and documented diagnosis of Heart Failure Non-Preferred Criteria ACEIs: - Have tried 2 different preferred single entity agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days ACEI/CCB Combinations: - Have tried 2 different preferred ACEI/CCB agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days ACEI/Diuretic Combinations:
benazepril	ACCUPRIL (quinapril)	
captopril	ALTACE (ramipril)	
enalapril	EPANED (enalapril)	
fosinopril	LOTENSIN (benazepril)	
lisinopril	moexipril	
quinapril	perindopril	
ramipril	QBRELIS (lisinopril)	
trandolapril	VASOTEC (enalapril)	
	ZESTRIL (lisinopril)	
ACE INHIBITOR (ACEI) COMBINATIONS		
benazepril/amlodipine	ACCURETIC (quinapril/hydrochlorothiazide)	
benazepril/hydrochlorothiazide	LOTENSIN HCT (benazepril/hydrochlorothiazide)	
captopril/hydrochlorothiazide	LOTREL (benazepril/amlodipine)	
enalapril/hydrochlorothiazide	VASERETIC (enalapril/hydrochlorothiazide)	

fosinopril/hydrochlorothiazide	ZESTORETIC (lisinopril/hydrochlorothiazide)
lisinopril/hydrochlorothiazide	
quinapril/hydrochlorothiazide	
trandolapril/verapamil ER	
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs)	
irbesartan	ATACAND (candesartan)
losartan	AVAPRO (irbesartan)
olmesartan	BENICAR (olmesartan)
telmisartan	candesartan
valsartan tablet	COZAAR (losartan)
	EDARBI (azilsartan)
	eprosartan
	MICARDIS (telmisartan)
	valsartan solution
ARB COMBINATIONS	
ENTRESTO (valsartan/sacubitril) tablet ^{DUR+}	ATACAND HCT (candesartan/hydrochlorothiazide)
irbesartan/hydrochlorothiazide	AVALIDE (irbesartan/hydrochlorothiazide)
losartan/hydrochlorothiazide	AZOR (olmesartan/hydrochlorothiazide)
olmesartan/amlodipine	BENICAR HCT (olmesartan/hydrochlorothiazide)
olmesartan/hydrochlorothiazide	candesartan/hydrochlorothiazide
telmisartan/hydrochlorothiazide	DIOVAN-HCT (valsartan/hydrochlorothiazide)
valsartan/amlodipine	EDARBYCLOR (azilsartan/chlorthalidone)
valsartan/amlodipine/hydrochlorothiazide	ENTRESTO (valsartan/sacubitril) sprinkle capsule
valsartan/hydrochlorothiazide	EXFORGE (valsartan/amlodipine)
	EXFORGE HCT (valsartan/amlodipine/hydrochlorothiazide)
	olmesartan/amlodipine/hydrochlorothiazide
	telmisartan/amlodipine
	TRIBENZOR (olmesartan/amlodipine/hydrochlorothiazide)
	valsartan/sacubitril
DIRECT RENIN INHIBITORS	
	aliskiren
	TEKTRUNA (aliskiren)
DIRECT RENIN INHIBITOR COMBINATIONS	
	TEKTRUNA HCT (aliskiren/hydrochlorothiazide)

- Have tried 2 different preferred ACEI/Diuretic agents in the past 6 months **OR**
- 90 days of therapy with the requested agent in the past 105 days
- **ARBs:**
 - Have tried 2 different preferred single entity agents in the past 6 months **OR**
 - 90 days of therapy with the requested agent in the past 105 days
- **ARB/CCB and ARB/CCB/Diuretic Combinations:**
 - Have tried 1 preferred ARB/CCB agent in the past 6 months **OR**
 - 90 days of therapy with the requested agent in the past 105 days
- **ARB/Diuretic Combinations:**
 - Have tried 2 different preferred ARB/Diuretic agents in the past 6 months **OR**
 - 90 days of therapy with the requested agent in the past 105 days
- **Direct Renin Inhibitors:**
 - Documented diagnosis of Hypertension **AND**
 - Have tried 2 different preferred ACEI or ARB single-entity agents in the past 6 months **OR**
 - 90 days of therapy with the requested agent in the past 105 days
- **Direct Renin Inhibitor Combinations:**
 - Documented diagnosis of Hypertension **AND**
 - Have tried 2 different preferred ACEI or ARB diuretic agents in the past 6 months **OR**
 - 90 days of therapy with the requested agent in the past 105 days
 - Have tried 2 different preferred ACEI/Diuretic agents in the past 6 months **OR**
 - 90 days of therapy with the requested agent in the past 105 days

ANTIBIOTICS (GI) & RELATED AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
metronidazole tablet	AEMCOLO (rifamycin)	
neomycin	DIFICID (fidaxomicin)	
tinidazole	FIRVANQ (vancomycin)	
vancomycin oral solution	FLAGYL (metronidazole)	
	LIKMEZ (metronidazole)	
	metronidazole 125 mg tablet, 375 mg capsule	
	nitazoxanide	
	paromomycin	
	REBYOTA (fecal microbiota, live-jslm)	
	VANCOCIN (vancomycin)	
	vancomycin capsule	
	VOWST (fecal microbio spore, live-brpk)	
	XIFAXAN (rifaximin)	
ANTIBIOTICS (MISCELLANEOUS)		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
LINCOSAMIDE ANTIBIOTICS		Quantity Limit • 6 tablets/month: SIVEXTRO
clindamycin	CLEOCIN (clindamycin)	

	CELOCIN PEDIATRIC (clindamycin)	SIVEXTRO MANUAL PA ZYVOX MANUAL PA
MACROLIDES		
azithromycin	ERYPED (erythromycin ethylsuccinate) suspension	
clarithromycin	ERYTHROCIN (erythromycin stearate)	
clarithromycin ER	ZITHROMAX (azithromycin)	
E.E.S (erythromycin ethylsuccinate) suspension		
ERY-TAB (erythromycin)		
erythromycin		
erythromycin ethylsuccinate		
NITROFURANTOIN DERIVATIVES		
nitrofurantoin capsule	FURADANTIN (nitrofurantoin) suspension	
nitrofurantoin monohydrate macrocrystals	MACROBID (nitrofurantoin monohydrate macrocrystals)	
	nitrofurantoin suspension	
OXAZOLIDINONES		
	linezolid	
	SIVEXTRO (tedizolid)	
	ZYVOX (linezolid)	

ANTIBIOTICS (TOPICAL)		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
bacitracin ^{OTC}	CENTANY (mupirocin)	
bacitracin/polymyxin ^{OTC}	CENTANY AT (mupirocin)	
gentamicin sulfate	mupirocin cream	
mupirocin ointment	XEPI (ozenoxacin)	
neomycin/bacitracin/polymyxin ^{OTC}		

ANTIBIOTICS (VAGINAL)		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CLEOCIN (clindamycin)	clindamycin phosphate	
NUVESSA (metronidazole)	CLINDESSE (clindamycin)	
	SOLOSEC (secnidazole)	
	XACIATO (clindamycin)	

ANTICOAGULANTS			
PREFERRED AGENTS		NON-PREFERRED AGENTS	PA CRITERIA
LOW MOLECULAR WEIGHT HEPARIN (LMWH)			Non-Preferred Criteria • LMWH: - Have tried 1 preferred agent in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days • Oral: - Have tried 2 different preferred oral agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days
enoxaparin	ARIXTRA (fondaparinux)		
	fondaparinux		
	FRAGMIN (dalteparin)		
	LOVENOX (enoxaparin)		
ORAL			
ELIQUIS (apixaban)	dabigatran		
JANTOVEN (warfarin)	PRADAXA (dabigatran) pellet pack		
PRADAXA (dabigatran) capsule	SAVAYSA (edoxaban)		
warfarin	rivaroxaban		
XARELTO (rivaroxaban)			

ANTICONVULSANTS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ADJUVANTS		Minimum Age Limit • 6 months: DIACOMIT • 1 year: BANZEL, EPIDIOLEX • 2 years: ONFI, SYMPAZAN • 2 years: VALTOCO • 12 years: NAYZILAM Maximum Age Limit • 2 years: VIGAFYDE
carbamazepine	APTIOM (eslicarbazepine acetate)	
carbamazepine ER 12-hour capsule	BANZEL (rufinamide)	
DEPAKOTE ER (divalproex)	BRIVIACT (brivaracetam)	
DEPAKOTE SPRINKLE (divalproex)	carbamazepine ER 12-hour tablet	
divalproex	CARBATROL (carbamazepine)	
divalproex ER	DEPAKOTE (divalproex)	
divalproex sprinkle	DIACOMIT (stiripentol)	
EPIDIOLEX (cannabidiol)	ELEPSIA XR (levetiracetam)	
lacosamide	EPRONTIA (topiramate)	

lamotrigine	EQUETRO (carbamazepine)
lamotrigine blue, green, orange dose pack	Eslicarbazepine
levetiracetam	felbamate
levetiracetam ER	FELBATOL (felbamate)
oxcarbazepine tablet	FINTEPLA (fenfluramine)
tiagabine	FYCOMPA (perampanel)
topiramate	KEPPRA (levetiracetam)
topiramate sprinkle 15, 25 mg (generic Topamax)	KEPPRA XR (levetiracetam)
TRILEPTAL (oxcarbazepine) suspension	LAMICTAL (lamotrigine)
valproic acid	LAMICTAL XR (lamotrigine)
zonisamide	lamotrigine ER
	lamotrigine ODT
	lamotrigine ODT blue, green, orange dose pack
	MOTPOLY XR (lacosamide)
	oxcarbazepine suspension
	oxcarbazepine ER
	OXTELLAR XR (oxcarbazepine)
	QUDEXY XR (topiramate)
	ROWEEPRA (levetiracetam)
	rufinamide
	SABRIL (vigabatrin)
	SPRITAM (levetiracetam)
	SUBVENITE (lamotrigine)
	SUBVENITE (lamotrigine) blue, green, orange dose pack
	TEGRETOL (carbamazepine)
	TEGRETOL XR (carbamazepine)
	TOPAMAX TABLET (topiramate)
	TOPAMAX SPRINKLE (topiramate)
	topiramate ER capsule (generic Trokendi XR)
	topiramate ER sprinkle capsule (generic Qudexy XR)
	topiramate sprinkle 50 mg
	TRILEPTAL (oxcarbazepine) tablet
	TROKENDI XR (topiramate)
	vigabatrin
	VIGADRONE (vigabatrin)
	VIGAFYDE (vigabatrin)
	VIGPODER (vigabatrin)
	VIMPAT (lacosamide)
	XCOPRI (cenobamate)
	ZONISADE (zonisamide) suspension
	ZTALMY (ganaxolone)
HYDANTOINS	
DILANTIN (phenytoin)	
DILANTIN-125 (phenytoin)	
PHENYTEK (phenytoin)	
phenytoin	
phenytoin ER	
SELECTED BENZODIAZEPINES	
clobazam	DIASTAT (diazepam) rectal gel
diazepam rectal gel	LIBERVANT (diazepam)
NAYZILAM (midazolam)	ONFI (clobazam)
VALTOCO (diazepam)	SYMPAZAN (clobazam)
SUCCINIMIDES	
ethosuximide	CELONTIN (methsuximide)
	methsuximide
	ZARONTIN (ethosuximide)

Quantity Limit (per 31 days)

- **2 twin packs:** DIASTAT
- **2 packages:** NAYZILAM
- **5 devices:** VALTOCO

Non-Preferred Criteria

- Have tried 2 different preferred agents in the past 6 months **OR**
- Documented diagnosis of Seizure **AND**
- 90 days of therapy with the requested agent in the past 105 days

Banzel, Onfi, and Sympazan

- Documented diagnosis of Lennox-Gastaut Syndrome **and** have tried 1 preferred agent for Lennox-Gastaut Syndrome in the past 6 months **OR**
- Documented diagnosis of Seizure **and** 90 days of therapy with the requested agent in the past 105 days

DIACOMIT

- Documented diagnosis of Dravet Syndrome **AND**
- 1 claim for clobazam in the past 30 days

EPIDIOLEX

- Documented diagnosis of Dravet Syndrome, Lennox-Gastaut Syndrome, or Seizures associated with Tuberous Sclerosis Complex **OR**
- 1 claim for EPIDIOLEX in the past 30 days

FINTEPLA

- Requires clinical review

SABRIL Powder for Oral Solution

- Documented diagnosis of Infantile Spasms **OR**
- Have tried 2 different preferred agents in the past 6 months **OR**
- Documented diagnosis of Seizure **AND**
- 90 days of therapy with the requested agent in the past 105 days

TOPIRAMATE ER

- Documented diagnosis of Seizure **AND**
- 90 days of therapy with the requested agent in the past 105 days **OR**
- 30 days of therapy with topiramate IR in the past 6 months

VIGAFYDE

- Age ≤ 2 years **AND**
- Documented diagnosis of infantile spasms

XCOPRI

- Age ≥ 18 years

ANTIDEPRESSANTS, OTHER DUR+		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
bupropion	APLENZIN (bupropion)	Minimum Age Limit • 18 years: all agents Non-Preferred Criteria • Have tried 2 different preferred agents in the past 6 months OR • Have tried 1 preferred agent and 1 SSRI in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days AUVELITY and RALDESY • Requires clinical review DRIZALMA Sprinkles • Automatic approval issued with a diagnosis of Generalized Anxiety Disorder for 7-11 years of age DULOXETINE • Automatic approval issued with a diagnosis of Generalized Anxiety Disorder for 7-17 years of age ZURZUVAE MANUAL PA • 90 days of therapy with the requested agent in the past 105 days
bupropion SR	AUVELITY (bupropion/dextromethorphan)	
bupropion XL	desvenlafaxine ER	
mirtazapine	DESYREL (trazodone)	
trazodone	DRIZALMA SPRINKLE (duloxetine DR)	
TRINTELLIX (vortioxetine)	EFFEXOR XR (venlafaxine)	
venlafaxine	EMSAM (selegiline)	
venlafaxine ER capsule	FETZIMA (levomilnacipran)	
vilazodone	FORFIVO XL (bupropion)	
	MARPLAN (isocarboxazid)	
	NARDIL (phenelzine)	
	nefazodone	
	phenelzine	
	PRISTIQ (desvenlafaxine)	
	REMERON (mirtazapine)	
	tranylcypromine	
	Trazodone solution ^{NR}	
	venlafaxine ER tablet	
	VIIBRYD (vilazodone)	
	WELLBUTRIN SR (bupropion)	
	WELLBUTRIN XL (bupropion)	
	ZURZUVAE (zuranolone)	
ANTIDEPRESSANTS, SSRIs DUR+		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
citalopram solution, tablet	CELEXA (citalopram)	Minimum Age Limit • 6 years: ZOLOFT • 7 years: LEXAPRO, PROZAC • 8 years: fluvoxamine • 18 years: CELEXA, LUVOX CR, PAXIL, PROZAC 90 mg Maximum Age Limit • 60 years CELEXA Non-Preferred Criteria • Have tried 2 different preferred agents in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days
escitalopram	citalopram capsule	
fluoxetine capsule	fluoxetine solution, tablet	
fluvoxamine	fluoxetine DR capsule	
paroxetine tablet	fluvoxamine ER capsule	
paroxetine CR	LEXAPRO (escitalopram)	
paroxetine ER	paroxetine suspension, capsule	
sertraline tablet, solution	PAXIL (paroxetine)	
	PAXIL CR (paroxetine)	
	PROZAC (fluoxetine)	
	sertraline capsule	
	ZOLOFT (sertraline)	
ANTIEMETICS DUR+		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
5HT3 RECEPTOR BLOCKERS		Quantity Limit (per 31 days) • 6 tablets: AKYNZEO • 100 mL: ZOFRAN solution Non-Preferred Agents • Have tried 1 preferred agent in the past 6 months AKYNZEO MANUAL PA Note: Injectables in this class are closed to point of sale. PA required if not administered in clinic/hospital.
ondansetron solution, tablet	ANZIMET (dolasetron)	
ondansetron ODT 4 mg, 8 mg	granisetron	
	ondansetron ODT 16 mg tablet	
	SANCUSO (granisetron)	
ANTIEMETIC COMBINATIONS		
DICLEGIS (doxylamine/pyridoxine)	AKYNZEO (netupitant/palonosetron)	
	BONJESTA (doxylamine/pyridoxine)	
	doxylamine/pyridoxine	
CANNABINOIDS		
	dronabinol	
	MARINOL (dronabinol)	
NMDA RECEPTOR ANTAGONISTS		
aprepitant	EMEND (aprepitant)	
ANTIFUNGALS (ORAL) DUR+		

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
clotrimazole	ANCOBON (flucytosine)	Griseofulvin suspension - Automatic approval issued for 0-11 years of age Griseofulvin tablets - Automatic approval issued for 12-17 years of age Minimum Age Limit 18 years: CRESEMBA Non-Preferred Criteria - Have tried 2 different preferred agents in the past 6 months HIV Opportunistic Infection - Non-Preferred agent indicated for treatment (^) AND - Documented diagnosis of HIV CRESEMBA MANUAL PA SPORANOX - Requires clinical review
fluconazole	BREXAFEMME (ibrexafungerp)	
nystatin	CRESEMBA (isavuconazonium sulfate)	
terbinafine	DIFLUCAN (fluconazole)	
	flucytosine	
	griseofulvin	
	griseofulvin ultramicrosize	
	itraconazole	
	ketoconazole	
	NOXAFIL (posaconazole)	
	ORAVIG (miconazole)	
	Posaconazole	
	SPORANOX (itraconazole)	
	TOLSURA (itraconazole)	
	VFEND (voriconazole)	
	VIVJOA (oteseconazole)	
	voriconazole	

ANTIFUNGALS (TOPICAL) ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTIFUNGALS		Non-Preferred Criteria - Have tried 2 different preferred agents in the past 6 months MICOTRIN AC, MYCOZYL, and clotrimazole 30 mL solution - Require clinical review
ciclopirox cream, gel, solution, suspension	BENSAL HP (salicylic acid)	
clotrimazole cream, solution Rx & OTC	CILODAN (ciclopirox)	
econazole	ciclopirox shampoo	
ketoconazole cream, shampoo	clotrimazole solution (NDC 50228-0502-61)	
LUZU (luliconazole)	ERTACZO (sertaconazole)	
miconazole cream, powder, solution OTC	EXTINA (ketoconazole)	
miconazole/zinc oxide/petrolatum ointment	JUBLIA (efinaconazole)	
nystatin cream, ointment, powder	ketoconazole foam	
terbinafine OTC	KETODAN (ketoconazole)	
tolnaftate cream, solution OTC	LOPROX (ciclopirox)	
	luliconazole	
	MICOTRIN AC (clotrimazole)	
	MYCOZYL AC (clotrimazole)	
	MYCOZYL AP (miconazole)	
	naftifine	
	NAFTIN (naftifine)	
	oxiconazole	
	OXISTAT (oxiconazole)	
	tavaborole	
	VOTRIZA-AL (clotrimazole)	
	VUSION (miconazole/zinc oxide/petrolatum)	
ANTIFUNGAL/STEROID COMBINATIONS		
clotrimazole/betamethasone cream	clotrimazole/betamethasone lotion	
nystatin/triamcinolone		

ANTIFUNGALS (VAGINAL)

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
clotrimazole cream ^{OTC}	3-DAY VAGINAL CREAM (clotrimazole)	
clotrimazole-3 cream	GYNAZOLE 1 (butoconazole)	
miconazole kit ^{OTC}	terconazole suppository	
terconazole cream		

ANTIHIISTAMINES, MINIMALLY SEDATING AND COMBINATIONS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
MINIMALLY SEDATING ANTIHIISTAMINES		Non-Preferred Criteria

cetirizine capsule, solution, tablet ^{OTC}	cetirizine chewable tablet ^{OTC}	- Documented diagnosis of Allergy or Urticaria AND - Have tried 2 different preferred agents in the past 12 months
loratadine chewable tablet, ODT, solution, tablet ^{OTC}	CLARINEX (desloratadine)	
	desloratadine	
	levocetirizine	
MINIMALLY SEDATING ANTIHISTAMINE/DECONGESTANT COMBINATIONS		
cetirizine/pseudoephedrine	CLARINEX-D 12 HOUR (desloratadine/pseudoephedrine)	
loratadine/pseudoephedrine	fexofenadine/pseudoephedrine	
ANTIMIGRAINE AGENTS, ACUTE TREATMENT		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CGRP ORAL AND NASAL		Minimum Age Limit 6 years: MAXALT 12 years: almotriptan, sumatriptan/naproxen, ZOMIG nasal spray 18 years: FROVA, IMITREX, naratripin, NURTEC ODT, RELPAX, REYVOW, SYMBRAVO, TOSYMRA, UBRELVY, ZEMBRACE, ZOMIG tablets Quantity Limit (per 31 days) ORAL 4 tablets: REYVOW 50 mg 6 tablets: almotriptan, RELPAX, ZOMIG 8 tablets: NURTEC ODT, REYVOW 100 mg 9 tablets: naratriptan, FROVA, IMITREX, sumatriptan/naproxen, SYMBRAVO 12 tablets: MAXALT 16 tablets: UBRELVY NASAL 1 box: all agents CUMULATIVE Quantity Limit (per 31 days) INJECTABLES 4 injections: all agents Non-Preferred Criteria ORAL - Have tried 2 preferred oral agents in the past 90 days NASAL - Have tried 2 preferred oral agents in the past 90 days AND - Have tried a preferred nasal agent in the past 90 days Almotriptan and sumatriptan/naproxen - Automatic approval for 12-17 years of age NURTEC ODT and UBRELVY MANUAL PA - Documented diagnosis of Migraine AND - Have tried 2 different triptans in the past 6 months AND - No concurrent therapy with another CGRP agent or strong CYP3A4 inhibitor REYVOW - Documented diagnosis of Migraine AND - Have tried 2 different triptans in the past 90 days AND - Have tried preferred NURTEC ODT in the past 90 days SYMBRAVO - Requires clinical review ZAVZPRET MANUAL PA - Documented diagnosis of Migraine AND - Have tried 2 different triptans in the past 6 months AND - Have tried both NURTEC ODT and UBRELVY in the past 6 months AND - No concurrent therapy with another CGRP AGENT
NURTEC ODT (rimegepant)	ZAVZPRET (zavegepant)	
UBRELVY (ubrogepant)		
INJECTABLES		
sumatriptan	IMITREX (sumatriptan)	
	ZEMBRACE SYMTOUCH (sumatriptan)	
NASAL		
sumatriptan	IMITREX (sumatriptan)	
	TOSYMRA (sumatriptan)	
	zolmitriptan	
	ZOMIG (zolmitriptan)	
TRIPTANS AND RELATED AGENTS (ORAL) ^{DUR+}		
naratriptan	almotriptan	
rizatriptan	eletriptan	
sumatriptan	FROVA (frovatriptan)	
zolmitriptan	frovatriptan	
zolmitriptan ODT	IMITREX (sumatriptan)	
	MAXALT (rizatriptan)	
	MAXALT MLT (rizatriptan)	
	RELPAX (eletriptan)	
	REYVOW (lasmiditan)	
	sumatriptan/naproxen	
	ZOMIG (zolmitriptan)	

ANTIMIGRAINE AGENTS, PROPHYLAXIS			
PREFERRED AGENTS		NON-PREFERRED AGENTS	PA CRITERIA
INJECTABLES			Preferred Injectables - History of 3 claims with the requested agent in the past 105 days OR - New starts require clinical review Non-preferred Injectables - Require clinical review AIMOVIG, AJOVY, and EMGALITY MANUAL PA VYEPTI MANUAL PA
AIMOVIG Autoinjector (erenumab-aooe) ^{DUR+}	EMGALITY Syringe (galcanezumab-gnlm) 300 mg/mL		
AJOVY Autoinjector (fremanezumab-vfrm) ^{DUR+}	VYEPTI (eptinezumab-jjmr)		
AJOVY Syringe (fremanezumab-vfrm) ^{DUR+}			
EMGALITY Pen (galcanezumab-gnlm) ^{DUR+}			
EMGALITY Syringe (galcanezumab-gnlm) 120 mg/mL ^{DUR+}			
ORAL			
	QULIPTA (atogepant)		
	NURTEC ODT (rimegepant)		

*ANTINEOPLASTICS SELECTED SYSTEMIC ENZYME INHIBITORS		
PREFERRED AGENTS		PA CRITERIA
BOSULIF (bosutinib) tablet	AFINITOR (everolimus)	FARYDAK MANUAL PA IBRANCE - Documented diagnosis of WD-DDLS for retroperitoneal sarcoma OR - All other indications require clinical review LENVIMA Documented diagnosis of thyroid cancer, hepatocellular carcinoma, or renal cell carcinoma AND - History of 1 claim for everolimus in the past 30 days AND - History of 1 anti-angiogenic agent in the past 2 years OR - All other indications require clinical review LYNPARZA Tablets - Documented diagnosis of ovarian cancer, fallopian tube or peritoneal cancer AND - History of platinum-based chemotherapy in the past 2 years OR All other indications require clinical review MANUAL PA
CAPRESLA (vandetanib)	AFINITOR DISPERZ (everolimus)	
COMETRIQ (cabozantinib)	AKEEGA (niraparib/abiraterone)	
COTELLIC (cobimetinib)	ALECENSA (alectinib)	
everolimus	ALUNBRIG (brigatinib)	
GILOTTRIF (afatinib)	AUGTYRO (repotrectinib)	
ICLUSIG (ponatinib)	AYVAKIT (avapritinib)	
imatinib	BALVERSA (erdafitinib)	
IMBRUVICA (ibrutinib)	BOSULIF (bosutinib) capsule	
INLYTA (axitinib)	BRAFTOVI (encorafenib)	
IRESSA (gefitinib)	BRUKINSA (zanubrutinib)	
JAKAFI (ruxolitinib)	CABOMETYX (cabozantinib)	
MEKINIST (trametinib)	CALQUENCE (acalabrutinib)	
NEXAVAR (sorafenib)	COPIKTRA (duvelisib)	
ROZLYTREK (entrectinib)	DANZITEN (nilotinib)	
SPRYCEL (dasatinib)	dasatinib	
STIVARGA (regorafenib)	DATROWAY (datopotomab deruxtecan-dlnk) ^{NR}	
SUTENT (sunitinib)	DAURISMO (glasdegib)	
TAFINLAR (dabrafenib)	ERIVEDGE (vismodegib)	
TARCEVA (erlotinib)	ERLEADA (apalutamide)	
TASIGNA (nilotinib)	erlotinib	
TURALIO (pexidartinib)	FOTIVDA (tivozanib)	
TYKERB (lapatinib)	FRUZAQIA (fruquintinib)	
VOTRIENT (pazopanib)	GAVRETO (pralsetinib)	
XALKORI (crizotinib)	gefitinib	
XTANDI (enzalutamide)	GLEEVEC (imatinib)	
ZELBORAF (vemurafenib)	IBRANCE (palbociclib)	
ZYDELIG (idelalisib)	IDHIFA (enasidenib)	
ZYKADIA (ceritinib)	IMKELDI (imatinib)	
	INQOVI (decitabine/cedazuridine)	
	INREBIC (fedratinib)	
	ITOVEBI (inavolisib)	
	IWILFIN (eflornithine)	
	JAYPIRCA (pirtobrutinib)	
	KISQALI (ribociclib)	
	KISQALI-FEMARA CO-PACK (ribociclib/letrozole)	
	KOSELUGO (selumetinib/vitamin E)	
	KRAZATI (adagrasib)	
	lapatinib	
	LAZCLUZE (lazertinib)	
	LENVIMA (lenvatinib)	
	LOBRENA (lorlatinib)	

	LUMAKRAS (sotorasib)	
	LYNPARZA (olaparib)	
	LYTGOBI (futibatinib)	
	MEKTOVI (binimetinib)	
	NERLYNX (neratinib)	
	NUBEQA (darolutamide)	
	nilotinib ^{NR}	
	ODOMZO (sonidegib)	
	OGSIVEO (nirogacestat)	
	OJEMDA (tovorafenib)	
	OJJAARA (momelotinib)	
	ONUREG (azacitidine)	
	ORGOVYX (relugolix)	
	pazopanib	
	PEMAZYRE (pemigatinib)	
	PIQRAY (alpelisib)	
	QINLOCK (ripretinib)	
	RETEVMO (selpercatinib)	
	REVUFORJ (revumenib)	
	REZLIDHIA (olutasidenib)	
	RUBRACA (rucaparib)	
	RYDAPT (midostaurin)	
	SCEMBLIX (asciminib)	
	sorafenib	
	sunitinib	
	TABRECTA (capmatinib)	
	TAGRISSO (osimertinib)	
	TALZENNA (talazoparib)	
	TAZVERIK (tazemetostat)	
	TECENTRIQ HYBREZA (atezolizumab/hyaluronidase-tqjs)	
	TEPMETKO (tepotinib)	
	TIBSOVO (ivosidenib)	
	TORPENZ (everolimus)	
	TRUQAP (capivasertib)	
	TUKYSA (tucatinib)	
	VANFLYTA (quizartinib)	
	VERZENIO (abemaciclib)	
	VITRAKVI (larotrectinib)	
	VIZIMPRO (dacomitinib)	
	VONJO (pacritinib)	
	VORANIGO (vorasidenib)	
	WELIREG (belzutifan)	
	XOSPATA (gilteritinib)	
	XPOVIO (selinexor)	
	ZEJULA (niraparib)	

ANTIOBESITY SELECT AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
SAXENDA (liraglutide)	orlistat	All agents MANUAL PA required
WEGOVY (semaglutide)	XENICAL (orlistat)	
ANTIPARASITICS (TOPICAL) ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
PEDICULICIDES		Minimum Age Limit • 2 months: permethrin 1% (OTC), permethrin 5% • 6 months: NATROBA, SKLICE • 2 years: piperonyl/pyrethrins (OTC) • 4 years: NATROBA • 6 years: OVIDE • 18 years: EURAX
NATROBA (spinosad)	lindane	
permethrin 1% cream ^{OTC}	malathion	
VANALICE (piperonyl butoxide/pyrethrins)	OVIDE (malathion)	
	SKLICE (ivermectin)	
	spinosad	

SCABICIDES		Non-Preferred Criteria • Pediculicides ○ Have tried 2 preferred topical lice agents in the past 90 days • Scabicides • Have tried permethrin 5% in the past 90 days
ivermectin	CROTAN (crotamiton)	
permethrin 5% cream	ELIMITE (permethrin)	
	EURAX (crotamiton)	
	STROMECTOL (ivermectin)	

ANTIPARKINSON'S AGENTS (INJECTABLE)		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	VYALEV (foscarnidopa/foslevodopa)	VYALEV • Requires clinical review

ANTIPARKINSON’S AGENTS (ORAL) ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTICHOLINERGICS		Non-Preferred Criteria • Documented diagnosis of Parkinson’s disease AND • Have tried 2 different preferred agents in the past 6 months OR • 90 days of therapy with a selegiline agent in the past 105 days
benztropine		
trihexyphenidyl		
COMT INHIBITORS		GOCOVRI • Documented diagnosis of Parkinson’s disease AND • 30 days of therapy with amantadine IR in the past 105 days AND • 30 days of therapy with a carbidopa/levodopa combination agent in the past 45 days
entacapone	OGENTYS (opicapone)	
	TASMAR (tocapone)	
	tolcapone	LODOSYN and INBRIJA • Documented diagnosis of Parkinson’s disease AND • 30 days of therapy with a carbidopa/levodopa combination agent in the past 45 days
DOPAMINE AGONISTS		
pramipexole	NEUPRO (rotigotine)	
ropinirole	pramipexole ER	NOURIANZ • Documented diagnosis of Parkinson’s Disease AND • Have tried 1 preferred carbidopa/levodopa combination agent in the past 30 days AND • 30 days of therapy with a preferred adjunctive therapy in the past 45 days
	ropinirole ER	
MAO-B INHIBITORS		
selegiline	AZILECT (rasagiline)	XADAGO • Documented diagnosis of Parkinso’ s Disease AND • History of 30 days of therapy with a carbidopa/levodopa combination agent in the past 45 days AND • History of 30 days of therapy with a selegiline agent the in past 45 days
	rasagiline	
	XADAGO (safinamide)	
	ZELAPAR (selegiline)	
OTHERS		
amantadine	carbidopa/levodopa ODT	
bromocriptine	carbidopa/levodopa/entacapone	
carbidopa	CREXONT (carbidopa/levodopa)	
carbidopa/levodopa tablet	DHIVY (carbidopa/levodopa)	
carbidopa/levodopa ER	DUOPA (carbidopa/levodopa)	
	GOCOVRI (amantadine)	
	INBRIJA (levodopa)	
	LODOSYN (carbidopa)	
	NOURIANZ (istradefylline)	
	OSMOLEX ER (amantadine)	
	RYTARY (carbidopa/levodopa)	
	SINEMET (carbidopa/levodopa)	
	STALEVO (carbidopa/levodopa/entacapone)	

ANTIPSORIATICS (TOPICAL)		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
calcipotriene cream	calcipotriene foam, ointment, solution	
ENSTILAR (calcipotriene/betamethasone)	calcipotriene/betamethasone	
TACLONEX (calcipotriene/betamethasone)	calcitriol ointment	
	DUOBRII (halobetasol/tazarotene)	
	SORILUX (calcipotriene)	
	tazarotene	
	VECTICAL (calcitriol)	
	VTAMA (tapinarof)	
	ZORYVE (roflumilast)	

ANTIPSYCHOTICS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
INJECTABLE, ATYPICALS ^{DUR+}		Concurrent Therapy Limit for Age < 18 years • 90 days with ≥ 2 agents in the last 120 days will require a MANUAL PA

ABILIFY ASIMTUFII (aripiprazole)	ERZOFRI (paliperidone palmitate)
ABILIFY MAINTENA (aripiprazole)	GEODON (ziprasidone)
ARISTADA, ARISTADA INITIO (aripiprazole lauroxil)	olanzapine
INVEGA HAFYERA (paliperidone)	risperidone ER
INVEGA SUSTENNA (paliperidone palmitate)	RYKINDO (risperidone)
INVEGA TRINZA (paliperidone)	ziprasidone
PERSERIS (risperidone)	ZYPREXA (olanzapine)
RISPERIDAL CONSTA (risperidone)	ZYPREXA RELPREVV (olanzapine)
UZEDY (risperidone)	
ORAL DUR+	
aripiprazole tablet	ABILIFY (aripiprazole)
asenapine	ABILIFY MYCITE (aripiprazole)
clozapine tablet	ADASUVE (loxapine)
fluphenazine	aripiprazole ODT, solution
haloperidol	CAPLYTA (lumateperone)
haloperidol lactate	chlorpromazine
olanzapine	clozapine ODT
perphenazine	CLOZARIL (clozapine)
perphenazine/amitriptyline	COBENFY (xanomeline/trospium)
quetiapine	FANAPT (iloperidone)
quetiapine ER	GEODON (ziprasidone)
risperidone	IGALMI (dexmedetomidine)
thioridazine	INVEGA (paliperidone)
trifluoperazine	LATUDA (lurasidone)
VRAYLAR (cariprazine)	lurasidone
ziprasidone	LYBALVI (olanzapine/samidorphan)
	NUPLAZID (pimavanserin)
	olanzapine/fluoxetine
	OPIPZA (aripiprazole)
	paliperidone ER
	REXULTI (brexpiprazole)
	RISPERDAL (risperidone)
	SAPHRIS (asenapine)
	SEROQUEL (quetiapine)
	SEROQUEL XR (quetiapine ER)
	SYMBYAX (olanzapine/fluoxetine)
	VERSACLOZ (clozapine)
	ZYPREXA, ZYPREXA ZYDIS (olanzapine)
TRANSDERMAL, ATYPICALS	
	SECUADO (asenapine)

Minimum Age Limit

- **3 years:** HALDOL
- **5 years:** RISPERDAL, thioridazine
- **6 years:** ABILIFY, trifluoperazine
- **10 years:** LATUDA, SAPHRIS, SEROQUEL, SYMBYAX
- **12 years:** INVEGA, molindone, perphenazine, pimozide, thiothixene
- **13 years:** REXULTI, ZYPREXA
- **18 years:** ABILIFY MYCITE, CAPLYTA, CLOZARIL, COBENFY, FANAPT, fluphenazine, GEODON, loxapine, LYBALVI, NUPLAZID, perphenazine/amitriptyline, SECUADO, VRAYLAR, and all injectable agents

Quantity Limit

- **3 syringes/year:** ARISTADA INITIO

Non-Preferred Criteria Atypical Agents

- Have tried 2 preferred agents in the past 12 months **OR**
- 30 days of therapy with the requested agent in the past 180 days

ARISTADO INTIO, ARISTADO ER, INVEGA SUSTENNA, INVEGA TRINZA, PERSERID AND ZYPREXA RELPREEV

- Documented diagnosis of schizophrenia or schizoaffective disorder

ABILIFY MAINTENA, ABILIFY ASIMTUFII, or RISPERDAL CONSTA

- Documented diagnosis of schizophrenia, schizoaffective disorder or bipolar disorder

INVEGA HAFYERA

- Documented diagnosis of schizophrenia or schizoaffective disorder **AND**
- 4 claims for INVEGA SUSTENNA in the past year **OR**
- 1 claim for INVEGA TRINZA in the past year **OR**
- 1 claim for INVEGA HAFYERA in the past year

ERZOFRI, OPIPZA and risperidone ER

- Require clinical review

NUPLAZID

- Documented diagnosis of Parkinson s Disease

VRAYLAR

- Documented diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder **OR**
- Documented diagnosis major depressive disorder **AND**
 - o 30 days of therapy with an antidepressant in the past 45 days **OR**
 - o 1 claim for a 90-day supply of an antidepressant in the past 105 days

ANTIRETROVIRALS DUR+			
PREFERRED AGENTS		NON-PREFERRED AGENTS	PA CRITERIA
CAPSID INHIBITORS			Non-Preferred Criteria • 1 claim with the requested agent in the past 105 days STRIBILD MANUAL PA SUNLENCA • Requires clinical review TROGARZO • Requires clinical review TYBOST MANUAL PA
	SUNLENCA (lenacapavir)		
CD4 DIRECTED ATTACHMENT INHIBITORS			
	RUKOBIA (fostemsavir)		
CD4 DIRECTED HIV-1 INHIBITORS			
	TROGARZO (ibalizumab-uiyk)		
COMBINATION PRODUCTS NRTIs			
abacavir/lamivudine	COMBIVIR (lamivudine/zidovudine)		
CABENUVA (cabotegravir/rilpivirine)	EPZICOM (abacavir/lamivudine)		
DOVATO (dolutegravir/lamivudine)			
lamivudine/zidovudine			
COMBINATION PRODUCTS NUCLEOSIDE AND NUCLEOTIDE ANALOG RTIs			

DESCOVY (emtricitabine/tenofovir alafenamide)	TRUVADA (emtricitabine/tenofovir)	
emtricitabine/tenofovir		
COMBINATION PRODUCTS NUCLEOSIDE AND NUCLEOTIDE ANALOG AND NON-NUCLEOSIDE RTIs		
DELSTRIGO (doravirine/lamivudine/tenofovir)	ATRIPLA (efavirenz/emtricitabine/tenofovir)	
efavirenz/emtricitabine/tenofovir	CIMDUO (lamivudine/tenofovir)	
ODEFSEY (emtricitabine/rilpivirine/tenofovir)	COMPLERA (emtricitabine/rilpivirine/tenofovir)	
COMBINATION PRODUCTS PROTEASE INHIBITORS		
lopinavir/ritonavir	KALETRA (lopinavir/ritonavir)	
ENTRY INHIBITORS CCR5 CO-RECEPTOR ANTAGONISTS		
	maraviroc	
	SELZENTRY (maraviroc)	
ENTRY INHIBITORS FUSION INHIBITORS		
	FUZEON (enfuvirtide)	
INTEGRASE STRAND TRANSFER INHIBITORS		
APRETUDE (cabotegravir)	cabotegravir ER	
ISENTRESS (raltegravir)	ISENTRESS HD (raltegravir)	
TIVICAY, TIVICAY PD (dolutegravir)	VOCABRIA (cabotegravir)	
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTI)		
EDURANT (rilpivirine)	etravirine	
efavirenz	INTELENCE (etravirine)	
	nevirapine, nevirapine ER	
	PIFELTRO (doravirine)	
NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI)		
abacavir	didanosine	
EMTRIVA (emtricitabine)	emtricitabine	
lamivudine	EPIVIR (lamivudine)	
ZIAGEN (abacavir)	RETROVIR (zidovudine)	
zidovudine	stavudine	
	VIREAD (tenofovir disoproxil fumarate)	
PHARMACOENHANCER CYTOCHROME P450 INHIBITORS		
	TYBOST (cobicistat)	
PROTEASE INHIBITORS (NON-PEPTIDIC)		
PREZISTA (darunavir)	APTIVUS (tipranavir)	
	darunavir	
	PREZCOBIX (darunavir/cobicistat)	
PROTEASE INHIBITORS (PEPTIDIC)		
atazanavir	fosamprenavir	
EVOTAZ (atazanavir/cobicistat)	LEXIVA (fosamprenavir)	
ritonavir	NORIVIR (ritonavir)	
	REYATAZ (atazanavir)	
	VIRACEPT (nelfinavir)	
SINGLE PRODUCT REGIMENS		
BIKTARVY (bictegravir/emtricitabine/tenofovir)	efavirenz/lamivudine/tenofovir	
GENVOYA (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)	JULUCA (dolutegravir/rilpivirine)	
SYMFI (efavirenz/lamivudine/tenofovir)	rilpivirine ER	
SYMFI LO (efavirenz/lamivudine/tenofovir)	STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate)	
TRIUMEQ (abacavir/dolutegravir/lamivudine)	SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)	
TRIUMEQ PD (abacavir/dolutegravir/lamivudine)		
ANTIVIRALS, ORAL		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA

ANTI-CYTOMEGALOVIRUS AGENTS	
valganciclovir tablet	LIVTENCITY (maribavir)
	PREVYMIS (letermovir)
	VALCYTE (valganciclovir)
	valganciclovir solution
ANTI-HERPETIC AGENTS	
acyclovir	SITAVIG (acyclovir)
famciclovir	VALTREX (valacyclovir)
valacyclovir	
ANTI-INFLUENZA AGENTS	
oseltamivir	FLUMADINE (rimantadine)
	RAPIVAB (peramivir)
	RELENZA (zanamivir)
	rimantadine
	TAMIFLU (oseltamivir)
	XOFLUZA (baloxavir)

PREVYMIS

Requires clinical review

Valganciclovir solution

Automatic approval issued for 0-12 years of age

ANTIVIRALS, TOPICAL		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ZOVIRAX (acyclovir) cream	acyclovir	
	DENAVIR (penciclovir)	
	penciclovir	
	XERESE (acyclovir/hydrocortisone)	
	ZOVIRAX (acyclovir) ointment	

AROMATASE INHIBITORS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
anastrozole	ARIMIDEX (anastrozole)	
exemestane	AROMASIN (exemestane)	
letrozole	FEMARA (letrozole)	

ATOPIC DERMATITIS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ADBRY (tralokinumab-ldrm)	CIBINQO (abrocitinib)	Minimum Age Limit 3 months: EUCRISA 2 years: ELIDEL, tacrolimus 0.03% 12 years: OPZELURA 16 years: tacrolimus 0.1%
ADBRY Autoinjector (tralokinumab-ldrm)	EBGLYSS Pen (lebrikizumab-lbkz)	
DUPIXENT (dupilumab) ^{DUR+}	NEMLUVIO (nemolizumab-ilto)	
ELIDEL (pimecrolimus)	OPZELURA (ruxolitinib)	
EUCRISA (crisaborole) ^{DUR+}	ZORYVE (roflumilast) 0.15% cream	
pimecrolimus		
tacrolimus		

ADBRY

MANUAL PA

CIBINQO

Requires clinical review

DUPIXENT

1 claim with DUPIXENT in the past 60 days

OR

New starts require clinical review (see manual PA links below)

Asthma

MANUAL PA

Atopic Dermatitis

MANUAL PA

Bullous Pemphigoid

MANUAL PA

COPD

MANUAL PA

Eosinophilic Esophagitis

MANUAL PA

Nasal Polyposis

MANUAL PA

Prurigo Nodularis

MANUAL PA

EBGLYSS

Requires clinical review

EUCRISA

30 days of therapy with a calcineurin inhibitor or topical steroid in the past 6 months

OPZELURA

30 days of therapy with ELIDEL, EUCRISA or tacrolimus in the past 6 months

BETA BLOCKERS, ANTIANGINALS & SINUS NODE AGENTS			DUR+
PREFERRED AGENTS		NON-PREFERRED AGENTS	PA CRITERIA
ANTIANGINALS			ASPRUZYO SPRINKLE - Requires clinical review Ranolazine ER - Documented diagnosis of angina AND 1 claim for a calcium channel blocker, beta-blocker, nitrate, or combination agent in the past 30 days OR 90 days of therapy with the requested agent in the past 105 days Non-Preferred Criteria - Have tried 2 different preferred agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days COREG CR - Documented diagnosis of hypertension AND - Have tried generic carvedilol AND 1 preferred agent in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days CORLANOR MANUAL PA HEMANGEOL - Documented diagnosis of infantile hemangioma
		ASPRUZYO SPRINKLE (ranolazine)	
		ranolazine ER	
BETA- AND ALPHA-BLOCKERS			
carvedilol		carvedilol ER	
labetalol		COREG (carvedilol)	
		COREG CR (carvedilol)	
BETA-BLOCKER/DIURETIC COMBINATIONS			
atenolol/chlorthalidone		TENORETIC (atenolol/chlorthalidone)	
bisoprolol/hydrochlorothiazide		ZIAC (bisoprolol/hydrochlorothiazide)	
metoprolol/hydrochlorothiazide			
propranolol/hydrochlorothiazide			
BETA-BLOCKERS			
acebutolol		BETAPACE (sotalol)	
atenolol		BETAPACE AF (sotalol)	
bisoprolol		betaxolol	
HEMANGEOL (propranolol)		BYSTOLIC (nebivolol)	
metoprolol succinate		INDERAL LA (propranolol)	
metoprolol tartrate		INDERAL XL (propranolol)	
nadolol		INNOPRAN XL (propranolol)	
nebivolol		KAPSPARGO SPRINKLE (metoprolol succinate)	
pindolol		LOPRESSOR (metoprolol tartrate)	
propranolol		SOTYLIZE (sotalol)	
propranolol ER		TENORMIN (atenolol)	
SORINE (sotalol)		TOPROL XL (metoprolol succinate)	
sotalol			
sotalol AF			
timolol			
SINUS NODE AGENTS			
		CORLANOR (ivabradine)	
		ivabradine	

BILE SALTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ursodiol	BYLVAY (odevixibat)	
	CHENODAL (chenodiol)	
	IQIRVO (elafibranor)	
	LIVDELZI (seladelpar)	
	LIVMARLI (maralixibat)	
	OCALIVA (obeticholic acid)	
	RELTONE (ursodiol)	
	URSO FORTE (ursodiol)	

BLADDER RELAXANT PREPARATIONS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
MYRBETRIQ (mirabegron)	darifenacin ER	Non-Preferred Criteria Have tried 2 different preferred agents in the past 6 months
oxybutynin	DETROL (tolterodine)	
oxybutynin ER	DETROL LA (tolterodine)	
solifenacin	fesoterodine	
	GEMTESA (vibegron)	
	mirabegron ER	
	tolterodine	
	tolterodine ER	
	TOVIAZ (fesoterodine)	
	trospium	
	trospium ER	
	VESICARE (solifenacin)	

		VESICARE LS (solifenacin)		
BONE RESORPTION SUPPRESSION AND RELATED AGENTS ^{DUR+}				
PREFERRED AGENTS		NON-PREFERRED AGENTS	PA CRITERIA	
BISPHOSPHONATES			Non-Preferred Criteria - Documented diagnosis of osteoporosis or osteopenia AND - Have tried 2 different preferred agents in the past 6 months	
alendronate tablet	ACTONEL (risedronate)			
ibandronate tablet	alendronate solution			
risedronate	ATELVIA (risedronate)			
	BINOSTO (alendronate)			
	FOSAMAX (alendronate)			
	FOSAMAX PLUS D (alendronate/vitamin D3)			
	ibandronate syringe/vial			
	risedronate DR			
OTHERS				
FORTEO (teriparatide)	calcitonin salmon			
raloxifene	EVENITY (romosozumab-aqqg)			
	EVISTA (raloxifene)			
	JUBBONTI (denosumab-bbdz) ^{NR}			
	MIACALCIN (calcitonin salmon)			
	OSENVELT (denosumab-bmwo) ^{NR}			
	PROLIA (denosumab)			
	teriparatide			
	STOBOCLO (denoxumab-bmwo) ^{NR}			
	TYMLOS (abaloparatide)			
	WYOST (denosumab-bbdz) ^{NR}			
	XGEVA (denosumab)			
BPH AGENTS ^{DUR+}				
PREFERRED AGENTS		NON-PREFERRED AGENTS	PA CRITERIA	
5-ALPHA-REDUCTASE INHIBITORS			CARDURA, FLOMAX, PROSCAR, terazosin, or UROXATRAL Female - Documented State-accepted diagnosis Non-Preferred Criteria Male - Have tried 2 different preferred agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days ENTADFI - Requires clinical review	
dutasteride	AVODART (dutasteride)			
finasteride	ENTADFI (finasteride/tadalafil)			
	PROSCAR (finasteride)			
ALPHA BLOCKERS				
alfuzosin ER	CARDURA (doxazosin)			
doxazosin	CARDURA XL (doxazosin)			
tamsulosin	dutasteride/tamsulosin			
terazosin	FLOMAX (tamsulosin)			
	RAPAFLO (silodosin)			
	silodosin			
PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS				
	CIALIS (tadalafil)			
	tadalafil			
BRONCHODILATORS & COPD AGENTS				
PREFERRED AGENTS		NON-PREFERRED AGENTS		PA CRITERIA
ANTICHOLINERGIC-BETA AGONIST COMBINATIONS				Minimum Age Limit 6 years: SPIRIVA RESPIMAT SPIRIVA RESPIMAT - Automatic approval issued for diagnosis of asthma for ≥ 6 years of age BREZTRI AEROSPHERE 3 claims with BREZTRI AEROSPHERE in the past 105 days OR - New starts require clinical review Non-Preferred Criteria 1 claim for a preferred agent in the past 6 months OR 3 claims with the requested agent in the past 105 days
ANORO ELLIPTA (umeclidinium/vilanterol)	BEVESPI AEROSPHERE (glycopyrrolate/formoterol)			
COMBIVENT RESPIMAT (ipratropium/albuterol)	DUAKLIR PRESSAIR (aclidinium/formoterol)			
ipratropium/albuterol				
STIOLTO RESPIMAT (tiotropium/olodaterol)				
ANTICHOLINERGIC-BETA AGONIST-GLUCOCORTICOID COMBINATIONS				
	BREZTRI AEROSPHERE (budesonide/glycopyrrolate/formoterol) ^{DUR+}			
	TRELEGY ELLIPTA (fluticasone/umeclidinium/vilanterol)			

ANTICHOLINERGICS AND COPD AGENTS	
ATROVENT HFA (ipratropium)	DALIRESP (roflumilast)
INCRUSE ELLIPTA (umeclidinium)	OHTUVAYRE (ensifentrine)
ipratropium	roflumilast
SPIRIVA HANDIHALER (tiotropium)	SPIRIVA RESPIMAT (tiotropium) ^{DUR+}
	tiotropium
	TUDORZA PRESSAIR (aclidinium)
	YUPERI (revefenacin)
INHALATION SOLUTION ^{DUR+}	
albuterol	arformoterol
	BROVANA (arformoterol)
	formoterol, formoterol fumarate
	levalbuterol
	PERFOROMIST (formoterol)
INHALERS, LONG ACTING ^{DUR+}	
SEREVENT DISKUS (salmeterol)	
STRIVERDI RESPIMAT (olodaterol)	
INHALERS, SHORT ACTING	
albuterol HFA	levalbuterol HFA
VENTOLIN HFA (albuterol)	PROAIR DIGIHALER (albuterol)
	XOPENEX HFA (levalbuterol)
ORAL	
albuterol IR	albuterol ER
terbutaline	

Minimum Age Limit

- **4 years:** SEREVENT, XOPENEX HFA
- **6 years:** XOPENEX Solution
- **18 years:** BROVANA, PERFOROMIST, STRIVERDI RESPIMAT

Quantity Limit (per 31 days)

- **10.7 units** BREZTRI AEROSPHERE

XOPENEX HFA and Solution

- 1 claim for a preferred albuterol (inhaler or vials) in the past 30 days

CALCIUM CHANNEL BLOCKERS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
LONG-ACTING		Quantity Limit (per 21 days) • 252 capsules: nimodipine • 2520 mL: nimodipine Non-Preferred Criteria Long Acting • Have tried 2 different preferred Long Acting CCB agents in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days Non-Preferred Criteria Short Acting • Have tried 2 different preferred Short Acting CCB agents in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days Nimodipine • Documented diagnosis of subarachnoid hemorrhage in the past 45 days AND • Duration of therapy limited to 21 days
amlodipine	CARDIZEM CD (diltiazem)	
CARTIA XT (diltiazem)	CARDIZEM LA (diltiazem)	
diltiazem ER 24 HR	diltiazem ER 12 HR	
diltiazem CD 24 HR	diltiazem LA 24 HR	
diltiazem XR 24 HR	KATERZIA (amlodipine)	
DILT-XR 24 HR (diltiazem)	levamlodipine	
felodipine	MATZIM LA (diltiazem)	
nifedipine ER	nisoldipine	
TAZTIA XT (diltiazem)	NORVASC (amlodipine)	
verapamil ER	PROCARDIA XL (nifedipine)	
verapamil SR	SULAR (nisoldipine)	
	TIADYLT ER (diltiazem)	
	TIAZAC (diltiazem)	
	verapamil PM	
	VERELAN PM (verapamil)	
SHORT-ACTING		
diltiazem	CARDIZEM (diltiazem)	
nicardipine	isradipine	
nifedipine	nimodipine capsule and solution	
verapamil	NORLIQVA (amlodipine)	
	NYMALIZE (nimodipine)	

CALORIC AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BOOST	All non-preferred caloric/nutritional agents (which are all other products except those specifically listed as preferred) require a manual prior authorization.	Non-Preferred Agents MANUAL PA
BREAKFAST ESSENTIALS		
BRIGHT BEGINNINGS		
DUOCAL		
ENSURE		
NUTREN		
OSMOLITE		

PEDIASURE		
PROMOD		
RESOURCE		
TWOCAL HN		
CEPHALOSPORINS AND RELATED ANTIBIOTICS (ORAL)		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BETA LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS		Non-Preferred Criteria All Cephalosporin Generations - Have tried 2 different preferred agents in the past 6 months Maximum Age Limit 18 years: cefdinir suspension
amoxicillin/clavulanate	amoxicillin/clavulanate ER	
	AUGMENTIN (amoxicillin/clavulanate)	
CEPHALOSPORINS FIRST GENERATION		
cefadroxil	cephalexin tablet	
cephalexin capsule, suspension		
CEPHALOSPORINS SECOND GENERATION		
cefaclor capsule	cefaclor ER	
cefprozil	cefaclor suspension	
cefuroxime		
CEPHALOSPORINS THIRD GENERATION		
cefdinir	cefixime suspension	
cefixime capsule	SUPRAX (cefixime)	
cefpodoxime		
COLONY STIMULATING FACTORS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
FULPHILA (pegfilgrastim-jmdb)	FYLNETRA (pegfilgrastim-pbbk)	
NEUPOGEN (filgrastim)	GRANIX (tbo-filgrastim)	
	LEUKINE (sargramostim)	
	NEULASTA, NEULASTA ONPRO (pegfilgrastim)	
	NIVESTYM (filgrastim-aafi)	
	NYVEPRIA (pegfilgrastim-apgf)	
	RELEUKO (filgrastim-ayow)	
	RYZNEUTA (efbemalenograstim alfa-vuxw) ^{NR}	
	ROLVEDON (eflapegrastim-xnst)	
	STIMUFEND (pegfilgrastim-fpgk)	
	UDENYCA, UDENYCA ONBODY (pegfilgrastim-cbqv)	
	ZARXIO (filgrastim-sndz)	
	ZIEXTENZO (pegfilgrastim-bmez)	
CYSTIC FIBROSIS AGENTS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
PULMOZYME (dornase alfa)	ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor)	Minimum Age Limit 1 month: KALYDECO granules 3 months: PULMOZYME 1 year: ORKAMBI 2 years: COLY-MYCIN M, TRIKAFTA granules 6 years: ALYFTREK, BETHKIS, KALYDECO tablet, KITABIS, SYMDEKO, TOBI, TOBI PODHALER, TRIKAFTA tablet 7 years: CAYSTON 18 years: BRONCHITOL Maximum Age Limit 2 years: ORKAMBI 75-94 mg granules 5 years: KALYDECO, ORKAMBI 100-125 mg granules, ORKAMBI 200-125 mg granules, TRIKAFTA granules 11 years: TRIKAFTA 50-25-37.5 mg tablets Preferred Agents - Documented diagnosis of Cystic Fibrosis OR - Require clinical review
tobramycin (generic TOBI)	BETHKIS (tobramycin)	
	BRONCHITOL (mannitol)	
	CAYSTON (aztreonam)	
	colistimethate	
	COLY-MYCIN M (colistin)	
	KALYDECO (ivacaftor)	
	KITABIS (tobramycin)	
	ORKAMBI (lumacaftor/ivacaftor)	

	SYMDEKO (tezacaftor/ivacaftor)	ALYFTREK MANUAL PA
	TOBI (tobramycin)	KALYDECO MANUAL PA
	TOBI PODHALER (tobramycin)	ORKAMBI MANUAL PA
	tobramycin (generic BETHKIS & KITABIS)	SYMDEKO MANUAL PA
	TRIKAFTA (elexacaftor/tezacaftor/ivacaftor)	TOBI PODHALER Require clinical review
		TRIKAFTA MANUAL PA

CYTOKINE & CAM ANTAGONISTS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ACTEMRA (tocilizumab) syringe, vial	ABRILADA (adalimumab-afzb)	Preferred Agents Criteria details found here Non-Preferred Agents - Require clinical review IV Administered Agents - Require clinical review
AVSOLA (infliximab-axxq)	ACTEMRA ACTPEN (tocilizumab)	
ENBREL (etanercept)	adalimumab-aaty	
HUMIRA (adalimumab)	adalimumab-adaz	
KINERET (anakinra)	adalimumab-adbm	
methotrexate	adalimumab-fkjp	
OLUMIANT (baricitinib)	adalimumab-ryvk	
ORENCIA CLICKJECT (abatacept)	AMJEVITA (adalimumab-atto)	
ORENCIA VIAL (abatacept)	ARCALYST (rilonacept)	
OTEZLA (apremilast)	BIMZELX (bimekizumab-bkzx)	
RINVOQ (upadacitinib)	CIMZIA (certolizumab)	
RINVOQ LQ (upadacitinib)	COSENTYX (secukinumab)	
SIMPONI (golimumab)	CYLTEZO (adalimumab-adbm)	
TALTZ (ixekizumab)	ENTYVIO (vedolizumab)	
TYENNE Syringe, Vial (tocilizumab-aazg)	HADLIMA (adalimumab-bwwd)	
XELJANZ (tofacitinib) tablet	HULIO (adalimumab-fkjp)	
	HYRIMOZ (adalimumab-adaz)	
	IDACIO (adalimumab-aacf)	
	ILARIS (canakinumab)	
	ILUMYA (tildrakizumab-asmn)	
	INFLECTRA (infliximab-dyyb)	
	infliximab	
	JYLAMVO (methotrexate)	
	KEVZARA (sarilumab)	
	LITFULO (ritlecitinib)	
	OMVOH (mirikizumab-mrkz)	
	ORENCIA SYRINGE (abatacept)	
	OTREXUP (methotrexate)	
	OTULFI (ustekinumab-aauz)	
	PYZCHIVA (ustekinumab-ttwe)	
	RASUVO (methotrexate)	
	REMICADE (infliximab)	
	RENFLEXIS (infliximab-abda)	
	SILIQ (brodalumab)	
	SIMLANDI (adalimumab-ryvk)	
	SIMPONI ARIA (golimumab)	
	SKYRIZI (risankizumab-rzaa)	
	SOTYKTU (deucravacitinib)	
	SPEVIGO (spesolimab-sbzo)	
	STELARA (ustekinumab)	
	TOFIDENCE (tocilizumab-bavi)	
	TREMFYA (guselkumab)	
	TREXALL (methotrexate)	
	TYENNE Autoinjector (tocilizumab-aazg)	
	XATMEP (methotrexate)	
	XELJANZ (tofacitinib) solution	
	XELJANZ XR (tofacitinib)	

	YESINTEK (ustekinumab-kfce)	
	YUFLYMA (adalimumab-aaty)	
	YUSIMRY (adalimumab-aqvh)	
	ZYMFENTRA (infliximab-dyyb)	
ERYTHROPOIESIS STIMULATING PROTEINS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
EPOGEN (epoetin alfa)	ARANESP (darbepoetin alfa)	Non-Preferred Criteria • Documented diagnosis of cancer or chronic renal failure OR • Antineoplastic therapy in the past 6 months AND • Have tried a preferred RETACRIT or EPOGEN in the past 6 months OR • 1 claim for the requested agent in the past 105 days JESDUVROQ • Requires clinical review MIRCERA • Documented diagnosis of chronic renal failure in the past 2 years
MIRCERA (methoxy polyethylene glycol-epoetin-beta)	JESDUVROQ (daprodustat)	
RETACRIT (epoetin alfa-epbx)	PROCRT (epoetin alfa)	
	VAFSEO (vadadustat)	
FACTOR DEFICIENCY PRODUCTS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
FACTOR VIII		HEMLIBRA • 3 claims with HEMLIBRA in the past 105 days OR • New starts require clinical review MANUAL PA
ADVATE	ADYNOVATE	
AFSTYLA	ELOCTATE	
ALPHANATE	ESPEROCT	
ALTUVIIIIO	JIVI	
FEIBA	KCENTRA	
HEMOFIL M	OBIZUR	
HUMATE-P	VONVENDI	
KOATE		
KOGENATE FS		
KOVALTRY		
NOVOEIGHT		
NUWIQ		
RECOMBINATE		
WILATE		
XYNTHA, XYNTHA SOLOFUSE		
FACTOR IX		
ALPHANINE SD	BEQVEZ	
ALPROLIX	REBINYN	
BENEFIX		
IDELVION		
IXINITY		
PROFILNINE		
RIXUBIS		
OTHER HEMOPHILIA PRODUCTS		
COAGADEX (factor X)	ALHEMO (concizumab-mtci)	
FIBRYGA (fibrinogen)	CORIFACT (factor XIII)	
HEMLIBRA (emicizumab-kxwh) ^{DUR+}	HYMPAVZI (marstacimab-hncq)	
RIASTAP (fibrinogen)	NOVOSEVEN RT (factor VII)	
	SEVENFACT (factor VII)	
	TRETTEN (factor XIII)	
FIBROMYALGIA/NEUROPATHIC PAIN AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA

duloxetine (generic CYMBALTA)	CYMBALTA (duloxetine)	
gabapentin	DIRZALMA SPRINKLE (duloxetine)	
pregabalin	duloxetine 40 mg DR capsules (generic IRENKA)	
SAVELLA (milnacipran)	gabapentin ER	
	GABARONE (gabapentin)	
	GRALISE (gabapentin)	
	HORIZANT (gabapentin enacarbil)	
	LYRICA, LYRICA CR (pregabalin)	
	NEURONTIN (gabapentin)	
	pregabalin ER	

FLUOROQUINOLONES ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ciprofloxacin tablet	BAXDELA (delafloxacin)	Non-Preferred Criteria 1 claim for a preferred agent in the past 30 days CIPRO Suspension for Age < 12 Years - Documented diagnosis of Cystic Fibrosis or Anthrax infection or exposure OR - Documented diagnosis or Pneumonic plague or tularemia AND - History of doxycycline in the past 3 months OR 7 days of therapy with a preferred agent from 2 of the classes below in the past 3 months: ○Penicillin, 2nd or 3rd generation cephalosporin or macrolide LEVAQUIN Suspension for Age < 12 Years - Documented diagnosis of Anthrax infection or exposure OR - History of 7 days of therapy with a preferred from 2 of the following classes in the past 3 months ○ Penicillin, 2nd or 3rd generation cephalosporins, or macrolide AND - History of ciprofloxacin suspension in the past 3 months
levofloxacin tablet	CIPRO (ciprofloxacin)	
	ciprofloxacin suspension	
	levofloxacin solution	
	moxifloxacin	
	ofloxacin	

GAUCHER’S DISEASE		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ELELYSO (taliglucerase alfa)	CERDELGA (eliglustat)	
ZAVESCA (miglustat)	CEREZYME (imiglucerase)	
	miglustat	
	VPRIV (velaglucerase alfa)	
	YARGESA (miglustat)	

GENITAL WARTS & ACTINIC KERATOSIS AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CONDYLOX (podofilox)	CARAC (fluorouracil)	Minimum Age Limit 12 years: ALDARA, ZYCLARA 18 years: CONDYLOX, PICATO, VEREGEN
fluorouracil	EFUDEX (fluorouracil)	
imiquimod	VEREGEN (sinecatechins)	
podofilox	ZYCLARA (imiquimod)	

GI ULCER THERAPIES			
PREFERRED AGENTS		NON-PREFERRED AGENTS	PA CRITERIA
H2 RECEPTOR ANTAGONISTS			Prilosec 2.5 mg suspension - Automatic approval issued for 0-2 years of age Prilosec 10 mg suspension - Requires clinical review
famotidine	cimetidine		
	nizatidine		
	PEPCID (famotidine)		
OTHERS			
CARAFATE (sucralfate) suspension	CARAFATE (sucralfate) tablet		
misoprostol	CYTOTEC (misoprostol)		
sucralfate	DARTISLA (glycopyrrolate)		
	VOQUEZNA (vonoprazan)		
PROTON PUMP INHIBITORS			
esomeprazole capsule	DEXILANT (dexlansoprazole)		
NEXIUM (esomeprazole) packet	dexlansoprazole		
omeprazole	esomeprazole packet		

pantoprazole	KONVOME ^P (omeprazole/sodium bicarbonate)	
	lansoprazole Rx	
	NEXIUM (esomeprazole) capsule	
	omeprazole/sodium bicarbonate	
	PREVACID (lansoprazole)	
	PRILOSEC (omeprazole) packet	
	PROTONIX (pantoprazole)	
	rabeprazole	
	ZEGE ^R ID (omeprazole/sodium bicarbonate)	

GLUCOCORTICIDS (INHALED)		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
GLUCOCORTICIDS		Non-Preferred Criteria • Glucocorticoids ○ 2 preferred single-entity agents in the past 6 months OR ○ 90 days of therapy with the requested agent in the past 105 days • Glucocorticoid/Bronchodilator Combinations ○ 2 preferred combination agents in the past 6 months OR ○ 90 days of therapy with the requested agent in the past 105 days • Note: ○ Institutional-sized products are non-preferred AIRDUO DIGIHALER • Requires clinical review ARMONAIR DIGIHALER • Requires clinical review PROAIR DIGIHALER Require clinical review Minimum Age Limit • 18 years: AIRSUPRA Quantity Limit (per 31 days) • 2 inhalers: AIRSUPRA -- MANUAL PA
ASMANEX (mometasone)	ALVESCO (ciclesonide)	
budesonide 0.25 mg and 0.5 mg	ARMONAIR DIGIHALER (fluticasone)	
fluticasone diskus	ARNUITY ELLIPTA (fluticasone)	
fluticasone HFA	ASMANEX HFA (mometasone)	
PULMICORT FLEXHALER (budesonide)	budesonide 1 mg	
QVAR REDIHALER (beclomethasone)	FLOVENT HFA (fluticasone)	
	FLOVENT DISKUS (fluticasone)	
	PULMICORT (budesonide) nebulizer solution	
GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS		
ADVAIR DISKUS (fluticasone/salmeterol)	AIRDUO DIGIHALER (fluticasone/salmeterol)	
ADVAIR HFA (fluticasone/salmeterol)	AIRSUPRA (albuterol/budesonide)	
DULERA (mometasone/formoterol)	BREO ELLIPTA (fluticasone/vilanterol)	
fluticasone/salmeterol diskus	BREYNA (budesonide/formoterol)	
fluticasone/salmeterol HFA	budesonide/formoterol	
SYMBICORT (budesonide/formoterol)	fluticasone/vilanterol	
	WIXELA INHUB (fluticasone/salmeterol)	

GROWTH HORMONES ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
GENOTROPIN (somatropin)	HUMATROPE (somatropin)	All Agents • Age ≥ 18 years ○ Documented diagnosis of craniopharyngioma, panhypopituitarism, Prader-Willi Syndrome, Turner Syndrome or an approvable adult diagnosis OR ○ Documented procedure of cranial irradiation • Age < 18 years ○ Documented diagnosis of idiopathic short stature AND ○ Documented approvable pediatric diagnosis OR ○ Documented approvable pediatric diagnosis Minimum Age Limit • 3 years: NGENLA Maximum Age Limit • 18 years: NGENLA and SKYTROFA Non-Preferred Criteria • Documented approvable diagnosis for age as above AND • Have tried 1 preferred agent in the past 6 months OR
NORDITROPIN FLEXP ^R O (somatropin)	NGENLA (somatrogon-ghla)	
SKYTROFA (lonapegsomatropin-tcgd)	OMNITROPE (somatropin)	
	SEROSTIM (somatropin)	
	SOGROYA (somapacitan-beco)	
	VOXZOGO (vosoritide)	

		• 84 days of therapy with the requested agent in the past 105 days
	ZOMACTON (somatropin)	SKYTROFA • < 18 years AND • No history of diagnosis of Prader-Willi Syndrome AND • 28 days of therapy with a preferred short-acting growth hormone in the past 105 days
H. PYLORI COMBINATION TREATMENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
PYLERA (bismuth subcitrate potassium/metronidazole/ tetracycline)	bismuth subcitrate potassium/metronidazole/tetracycline	Quantity Limit • 1 treatment course/year: all agents
	lansoprazole/amoxicillin/clarithromycin	
	OMECLAMOX (omeprazole/clarithromycin/amoxicillin)	
	TALICIA (omeprazole/amoxicillin/rifabutin)	
	VOQUEZNA DUAL PAK (vonoprazan/amoxicillin)	
	VOQUEZNA TRIPLE PAK (vonoprazan/amoxicillin/clarithromycin)	
HEPATITIS B TREATMENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
entecavir	adefovir dipivoxil	
lamivudine HBV	BARACLUDE (entecavir)	
tenofovir disoproxil fumarate	VEMLIDY (tenofovir alafenamide)	
	VIREAD (tenofovir disoproxil fumarate)	
HEPATITIS C TREATMENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
MAVYRET (glecaprevir/pibrentasvir) [∞]	EPCLUSA (sofosbuvir/velpatasvir) [∞]	∞ EPCLUSA, HARVONI, MAVYRET, SOVALDI, VOSEVI, ZEPATIER • Require MANUAL PA Note: • EPCLUSA, HARVONI, MAVYRET and SOVALDI have FDA-approved pediatric indications
PEGASYS (peginterferon alfa-2a)	HARVONI (ledipasvir/sofosbuvir) [∞]	
ribavirin tablet	ledipasvir/sofosbuvir [∞]	
sofosbuvir/velpatasvir	ribavirin capsule	
	SOVALDI (sofosbuvir) [∞]	
	VIEKIRA PAK (ombitasvir/paritaprevir/ritonavir)	
	VOSEVI (sofosbuvir/velpatasvir/voxilaprevir) [∞]	
	ZEPATIER (elbasvir/grazoprevir) [∞]	
HEREDITARY ANGIOEDEMA TREATMENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BERINERT (C1 esterase inhibitor)	CINRYZE (C1 esterase inhibitor)	
icatibant	FIRAZYR (icatibant)	
	KALBITOR (ecallantide)	
	ORLADEYO (berotralstat)	
	RUCONEST (C1 esterase inhibitor)	
	SAJAZIR (icatibant)	
	TAKHZYRO (lanadelumab-flyo)	
HYPERURICEMIA & GOUT ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
allopurinol	ALOPRIM (allopurinol)	Non-Preferred Criteria • Have tried 2 different preferred agents in the past 6 months
colchicine tablet	colchicine capsule	
probenecid	COLCRYS (colchicine)	
probenecid/colchicine	febuxostat	
	GLOPERBA (colchicine)	
	MITIGARE (colchicine)	
	ULORIC (febuxostat)	
	ZYLOPRIM (allopurinol)	
HYPOGLYCEMIA TREATMENT		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BAQSIMI (glucagon)	GVOKE (glucagon) ^{Step Edit}	Minimum Age Limit • 1 year: BAQSIMI

GLUCAGEN (glucagon)		• 2 years: GVOKE • 6 years: ZEGALOGUE Quantity Limit (per 31 days) • 2 packs (or kits): BAQSIMI, glucagon, GVOKE, ZEGALOGUE Non-Preferred Criteria GVOKE • 1 claim with preferred BAQSIMI or ZEGALOGUE in the past 30 days
glucagon emergency kit		
glucagon vial		
ZEGALOGUE (dasiglucagon)		

HYPOGLYCEMICS, BIGUANIDES

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
metformin	BRYNOVIN solution (sitagliptin)	Non-Preferred Criteria • Have tried 2 different preferred DPP4 agents in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days Note: Concomitant use of a GLP-1 agent and a DPP-4 agent requires clinical review Minimum Age Limit • 18 years: BRYNOVIN solution
metformin ER (generic GLUCOPHAGE XR)	GLUMETZA (metformin)	
JANUMET (sitagliptin/metformin)	metformin ER (generic FORTAMET)	
JANUMET XR (sitagliptin/metformin)	metformin ER (generic GLUMETZA)	
JANUVIA (sitagliptin)	metformin solution	
JENTADUETO (linagliptin/metformin)	RIOMET (metformin)	
TRADJENTA (linagliptin)	alogliptin	
	alogliptin/metformin	
	JENTADUETO XR (linagliptin/metformin)	
	KAZANO (alogliptin/metformin)	
	KOMBIGLYZE XR (saxagliptin/metformin)	
	NESINA (alogliptin)	
	ONGLYZA (saxagliptin)	
	OSENI (alogliptin/pioglitazone)	
	saxagliptin	
	saxagliptin/metformin ER	
	sitagliptin	
	sitagliptin/metformin	
	ZITUVIMET (sitagliptin/metformin)	
	ZITUVIMET XR (sitagliptin/metformin)	
	ZITUVIO (sitagliptin)	

HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BYETTA (exenatide)	BYDUREON (exenatide)	Minimum Age Limit • 10 years: BYDUREON BCISE, TRULICITY, VICTOZA • 18 years: BYETTA, BMOUNJARO, OZEMPIC, RYBELSUS Preferred Criteria • Documented diagnosis of Type 2 Diabetes AND • No history of SAXENDA or WEGOVY in the past 30 days OR • No documented diagnosis for Type 2 Diabetes AND • 84 days of therapy with the requested agent in the past 105 days Non-Preferred Criteria • Documented diagnosis of Type 2 Diabetes AND • No history of SAXENDA or WEGOVY in the past 30 days AND • 84 days of therapy with TRULICITY in the past 6 months AND • 84 days of therapy with either preferred BYETTA or VICTOZA in the past 6 months OR • Documented diagnosis of Type 2 Diabetes AND • 84 days of therapy with the request agent in the past 105 days Note: • Concomitant use of a GLP-1 agonist and a DPP-4 agent requires clinical review. • Please see the PDL category Anti-obesity Select Agents for a list of covered agents. RYBELSUS 1.5 mg and 3 mg Require clinical review
TRULICITY (dulaglutide)	exenatide	
VICTOZA (liraglutide)	liraglutide	
	MOUNJARO (tirzepatide)	
	OZEMPIC (semaglutide)	
	RYBELSUS (semaglutide)	
	SOLIQUA (insulin glargine/lixisenatide)	
	SYMLINPEN (pramlintide)	
	XULTOPHY (insulin degludec/liraglutide)	

HYPOGLYCEMICS, INSULINS & RELATED AGENTS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
HUMALOG MIX 75/25 vial (insulin lispro/lispro protamine)	ADMELOG (insulin lispro)	Non-Preferred Criteria - Documented diagnosis of Diabetes Mellitus AND - Have tried 1 preferred agent in the past 6 months OR 1 claim with the requested agent in the past 105 days Quantity Limit Insulin quantity limits can be found here Note: - Insulin pen formulations are not covered for Long Term Care (LTC) beneficiaries.
HUMULIN 70/30 vial (insulin NPH/regular)	AFREZZA (insulin regular)	
HUMULIN N (insulin NPH)	APIDRA (insulin glulisine)	
HUMULIN R (insulin regular)	BASAGLAR (insulin glargine)	
HUMULIN R U-500 (insulin regular)	FIASP (insulin aspart/niacinamide)	
insulin aspart	HUMALOG; HUMALOG JUNIOR, KWIKPEN,	
insulin aspart protamine mix 70/30 vial	TEMPO PEN (insulin lispro)	
insulin lispro	HUMALOG MIX KWIKPEN 50/50, 75/25 (insulin lispro/lispro protamine)	
insulin lispro protamine mix 75/25 vial	HUMULIN 70/30 KWIKPEN (insulin N/regular)	
LANTUS (insulin glargine)	HUMULIN N KWIKPEN (insulin N)	
TOUJEO (insulin glargine)	insulin degludec	
TOUJEO MAX (insulin glargine)	insulin glargine	
	insulin glargine-yfqn	
	LEVEMIR (insulin detemir)	
	LYUMJEV (insulin lispro-aabc)	
	NOVOLIN 70/30 (insulin NPH/regular)	
	NOVOLIN N (insulin NPH)	
	NOVOLIN R (insulin regular)	
	NOVOLOG (insulin aspart)	
	NOVOLOG MIX 70/30 (insulin aspart protamine/aspart)	
	REZVOGLAR (insulin glargine-aglr)	
	SEMGLEE (insulin glargine-yfqn)	
	TRESIBA (insulin degludec)	
HYPOGLYCEMICS, MEGLITINIDES ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
nateglinide		
repaglinide		
HYPOGLYCEMICS, SODIUM GLUCOSE COTRANSPORTER-2 (SGLT-2) INHIBITORS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
SGLT-2 INHIBITORS		Non-Preferred Criteria - Have tried 2 different preferred SGLT-2 inhibitors in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days
FARXIGA (dapagliflozin)	dapagliflozin	
JARDIANCE (empagliflozin)	INPEFA (sotagliflozin)	
	INVOKANA (canagliflozin)	
	STEGLATRO (ertugliflozin)	
SGLT-2 INHIBITOR COMBINATIONS		
GLYXAMBI (empagliflozin/linagliptin)	dapagliflozin/metformin ER	
SYNJARDY (empagliflozin/metformin)	INVOKAMET (canagliflozin/metformin)	
SYNJARDY XR (empagliflozin/metformin)	INVOKAMET XR (canagliflozin/metformin)	
TRIJARDY XR (empagliflozin/linagliptin/metformin)	QTERN (dapagliflozin/saxagliptin)	
	SEGLUROMET (ertugliflozin/metformin)	
	STEGLUJAN (ertugliflozin/sitagliptin)	
	XIGDUO XR (dapagliflozin/metformin)	
HYPOGLYCEMICS, THIAZOLIDINEDIONES (TZDs) and TZD Combinations		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
pioglitazone	ACTOPLUS MET (pioglitazone/metformin)	
pioglitazone/metformin	ACTOS (pioglitazone)	
pioglitazone/glimepiride	DUETACT (pioglitazone/glimepiride)	
IDIOPATHIC PULMONARY FIBROSIS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
OFEV (nintedanib)	ESBRIET (pirfenidone)	All Agents

		Documented diagnosis of Idiopathic Pulmonary Fibrosis
	pirfenidone	OFEV - Documented diagnosis of Idiopathic Pulmonary Fibrosis OR 90 days of therapy with Ofev in the past 105 days

ESBRIET or pirfenidone

IMMUNE GLOBULINS

Requires clinical review

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BIVIGAM	ALYGLO	
FLEBOGAMMA	ASCENIV	
GAMASTAN	CABLIVI	
GAMMAGARD	CUTAQUIG	
GAMMAGARD S-D	CUVITRU	
GAMUNEX-C	GAMMAKED	
HIZENTRA	GAMMAPLEX	
HYQVIA	OCTAGAM	
PANZYGA		
PRIVIGEN		
XEMBIFY		

IMMUNOLOGIC THERAPIES FOR ASTHMA

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
DUPIXENT (dupilumab) ^{DUR+}	CINQAIR (reslizumab)	CINQAIR Requires clinical review
FASENRA (benralizumab)	NUCALA (mepolizumab)	
XOLAIR (omalizumab)	TEZSPIRE (tezepelumab-ekko)	

See below for additional PA Criteria/DUR+ Rules

- DUPIXENT**
- 1 claim with DUPIXENT in the past 60 days **OR**
 - New starts require clinical review (see manual PA links below)
 - Asthma** [MANUAL PA](#)
 - Atopic Dermatitis** [MANUAL PA](#)
 - COPD** [MANUAL PA](#)
 - Eosinophilic Esophagitis** [MANUAL PA](#)
 - Nasal Polyposis** [MANUAL PA](#)
 - Prurigo Nodularis** [MANUAL PA](#)

- FASENRA**
- Requires clinical review [MANUAL PA](#)
- NUCALA**
- Requires clinical review
- TEZSPIRE**
- Requires clinical review
- XOLAIR**
- 1 claim with XOLAIR in the past 45 days **OR**
 - New starts require clinical review [MANUAL PA](#)

IMMUNOSUPPRESSIVE AGENTS, ORAL

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
AZASAN (azathioprine)	ASTAGRAF XL (tacrolimus)	Minimum Age Limit 13 years: RAPAMUNE 18 years: ZORTRESS Maximum Age Limit 12 years: PROGRAF Granules
azathioprine	ENVARBUS XR (tacrolimus)	
CELLCEPT (mycophenolate)	MYFORTIC (mycophenolate)	
cyclosporine	PROGRAF (tacrolimus)	
everolimus	REZUROCK (belumosudil)	
mycophenolate	ZORTRESS (everolimus)	
mycophenolic acid		
NEORAL (cyclosporine)		
RAPAMUNE (sirolimus)		
SANDIMMUNE (cyclosporine)		
sirolimus		
tacrolimus		

- Preferred Criteria**
- AZASAN**
 - Documented diagnosis of kidney transplant, RA, or a State-accepted diagnosis
 - CELLCEPT**
 - Documented diagnosis of heart, kidney, or liver transplant or a State-accepted diagnosis

- **GENGRAF, NEORAL, SANDIMMUNE**
 - Documented diagnosis of heart transplant, kidney transplant, liver transplant, psoriasis, RA, or a State-accepted diagnosis
- **Everolimus**
 - Documented diagnosis of kidney or liver transplant
- **RAPAMUNE**
 - Documented diagnosis of kidney transplant
- **Tacrolimus**
 - Documented diagnosis of heart, kidney, liver, or lung transplant or a State-accepted diagnosis

- Non-Preferred Criteria**
- **MYHIBBIN Suspension**
 - Documented diagnosis of heart, kidney, or liver transplant or a State-accepted diagnosis **AND**
 - 30 days of therapy with mycophenolate suspension in the past 105 days **OR**
 - 90 days of therapy with MYHIBBIN Suspension in the past 105 days
 - **ASTAGRAF XR or ENVARUSUS XR**
 - Documented diagnosis of heart, kidney, liver, or lung transplant or a State-accepted diagnosis **AND**
 - 30 days of therapy with tacrolimus IR in the past 105 days **OR**
 - 90 days of therapy with the requested agent in the past 105 days
 - **PROGRAF Granules**
 - Age ≤ 11 years **AND**
 - Documented diagnosis of heart, kidney, liver, or lung transplant or a State-accepted diagnosis
 - **MYFORTIC**
 - Documented diagnosis of kidney transplant or psoriasis
 - **ZORTRESS**
 - Documented diagnosis of kidney or liver transplant

INTRANASAL RHINITIS AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTICHOLINERGICS		Non-Preferred Criteria Corticosteroids • Documented diagnosis of allergic rhinitis AND • Have tried 1 different preferred agent in the past 6 months
ipratropium		
ANTIHIISTAMINE/CORTICOSTEROID COMBINATIONS		
	azelastine/fluticasone	
	DYMISTA (azelastine/fluticasone)	
	RYALTRIS (olopatadine/mometasone)	
ANTIHIISTAMINES		
azelastine	olopatadine	
	PATANASE (olopatadine)	
CORTICOSTEROIDS		
fluticasone	BECONASE AQ (beclomethasone)	
	flunisolide	
	mometasone	
	NASONEX (mometasone)	
	OMNARIS (ciclesonide)	
	QNASL (beclomethasone)	
	XHANCE (fluticasone)	
	ZETONNA (ciclesonide)	
IRON CHELATING AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
deferasirox (all manufacturers except those listed as non-preferred)	deferasirox (manufacturers starting with 45963, 62332)	JADENU MANUAL PA
	deferiprone 1,000 mg tablet	
deferiprone 500 mg tablet	EXJADE (deferasirox)	
FERRIPROX (deferiprone)	JADENU, JADENU SPRINKLE (deferasirox)	
IRRITABLE BOWEL SYNDROME/SHORT BOWEL SYNDROME AGENTS/SELECTED AGENTS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
IRRITABLE BOWEL SYNDROME CONSTIPATION ^{DUR+}		Minimum Age Limit • 1 year: GATTEx

LINZESS (linaclotide)	AMITIZA (lubiprostone)	• 6 years: LINZESS 72 mcg • 18 years: AMITIZA, IBSRELA, LINZESS 145 mcg & 290 mcg, MOTTEGRITY, MOVANTIK, MYTESI, RELISTOR, SYMPROIC, TRULANCE, VIBERZI Gender Limit • Female AMITIZA 8 mcg
lubiprostone	IBSRELA (tenapanor)	
TRULANCE (plecanatide)	MOTTEGRITY (prucalopride)	
	MOVANTIK (naloxegol)	
	prucalopride	
	RELISTOR (methylnaltrexone)	
	SYMPROIC (naldemedine)	
IRRITABLE BOWEL SYNDROME DIARRHEA		
dicyclomine	alosetron	
ED-SPAZ (hyoscyamine)	LOTRONEX (alosetron) ^{DUR+}	
hyoscyamine, hyoscyamine ER	VIBERZI (eluxadoline) ^{DUR+}	
HYOSYNE (hyoscyamine)		
LEVSIN, LEVSIN-SL (hyoscyamine)		
NULEV (hyoscyamine)		
OSCIMIN, OSCIMIN SL (hyoscyamine)		
SHORT BOWEL SYNDROME AND SELECTED GI AGENTS ^{DUR+}		
	GATTEX (teduglutide)	
	MYTESI (crofelemer)	
IRRITABLE BOWEL SYNDROME CONSTIPATION ^{DUR+}		
Chronic Idiopathic Constipation (CIC): Amitiza 24 mcg, LINZESS 72 mcg, LINZESS 145 mcg, MOTTEGRITY, TRULANCE • Preferred CIC Agents ○ Documented diagnosis of CIC in the past year AND ○ No history of GI or bowel obstruction • LINZESS 72 mcg ○ Age 6-17 years AND ○ Documented diagnosis of CIC or pediatric functional constipation in the past year AND ○ No history of GI or bowel obstruction • Non-Preferred CIC Agents ○ Documented diagnosis of CIC AND ○ No history of GI or bowel obstruction AND ○ Have tried 2 preferred CIC agents in the past 6 months OR ○ 1 claim with the requested agent in the past 105 days	Irritable Bowel Syndrome Constipation Dominant (IBS-C): AMITIZA 8 mcg, IBSRELA, LINZESS 290 mcg, TRULANCE • Preferred IBS-C Agents ○ Documented diagnosis of IBS-C in the past year AND ○ No history of GI or bowel obstruction • Non-Preferred IBS-C Agents ○ Documented diagnosis of IBS-C in the past year AND ○ No history of GI or bowel obstruction AND ○ Have tried 2 preferred IBS-C agents in the past 6 months OR ○ 1 claim with the requested agent in the past 105 days	Opioid Induced Constipation (OIC): AMITIZA 24 mcg, MOVANTIK, RELISTOR, SYMPROIC • Preferred OIC Agents ○ Documented diagnosis of OIC and chronic pain in the past year AND ○ No history of GI or bowel obstruction AND ○ 1 claim for an opioid in the past 30 days • Non-Preferred OIC Agents ○ All preferred criteria met AND ○ Have tried 1 preferred OIC agents in the past 6 months OR ○ 1 claim with the requested agent in the past 105 days • Relistor Injection ○ Above OIC criteria OR ○ Documented diagnosis of OIC and active cancer in the past year AND ○ No history of GI or bowel obstruction AND ○ 1 claim for an opioid in the past 30 days
IRRITABLE BOWEL SYNDROME DIARRHEA		
• VIBERZI [New starts require clinical review] Documented diagnosis of IBS D in the past year and 1 claim for Viberzi in the past 105 days ○ • LOTRONEX ○ 1 claim for LOTRONEX in the past 105 days OR ○ New starts require clinical review MANUAL PA • XIFAXAN (see Antibiotics, GI)		
SHORT BOWEL SYNDROME AND SELECTED GI AGENTS ^{DUR+}		
HIV/AIDS Non-infectious Diarrhea • MYTESI ○ Documented diagnosis of HIV/AIDS and non-infectious diarrhea in the past year AND ○ 1 claim for an antiretroviral in the past 30 days	Short Bowel Syndrome (SBS) • GATTEX ○ 1 claim for GATTEX in the past 105 days OR ○ New starts require clinical review	
LEUKOTRIENE MODIFIERS ^{DUR+}		

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
montelukast	ACCOLATE (zafirlukast)	Minimum Age Limit 12 years: ZYFLO & ZYFLO CR Non-Preferred Criteria - Have tried 2 different preferred agents in the past 6 months
zafirlukast	SINGULAIR (montelukast)	
	zileuton	
	ZYFLO (zileuton)	

LIPOTROPICS, OTHER (NON-STATINS)

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ACL INHIBITORS AND COMBINATIONS		Non-Preferred Criteria Fibric Acid Derivatives ○ Have tried 2 different preferred Fibric Acid Derivative agents in the past 6 months
	NEXLETOL (bempedoic acid)	
	NEXLIZET (bempedoic acid/ezetimibe)	
ANGIOPOIETIN-LIKE 3 INHIBITORS		JUXTAPID MANUAL PA
	EVKEEZA (evinacumab-dgnb)	
BILE ACID SEQUESTRANTS		KYNAMRO • Requires clinical review
cholestyramine	colesevelam	LEQVIO • Requires clinical review
cholestyramine light	COLESTID (colestipol)	
colestipol tablet	colestipol packet	NEXLETOL and NEXLIZET • Require clinical review
	PREVALITE (cholestyramine)	
	QUESTRAN (cholestyramine)	
	QUESTRAN LIGHT (cholestyramine)	
	WELCHOL (colesevelam)	
CHOLESTEROL ABSORPTION INHIBITORS		PRALUENT MANUAL PA
ezetimibe	ZETIA (ezetimibe)	REPATHA MANUAL PA
FIBRIC ACID DERIVATIVES		
fenofibrate	fenofibric acid	WELCHOL • Documented diagnosis of Type 2 Diabetes AND • 30 days of therapy with an antidiabetic agent in the past 6 months OR 90 days of therapy with WELCHOL in the past 105 days
gemfibrozil	FENOGLIDE (fenofibrate)	
	FIBRICOR (fenofibric acid)	
	LIPOFEN (fenofibrate)	
	LOPID (gemfibrozil)	
	TRICOR (fenofibrate)	
	TRILIPIX (fenofibric acid)	
MTP INHIBITOR		
	JUXTAPID (lomitapide)	
NIACIN		
niacin ER		
OMEGA-3 FATTY ACIDS		
omega-3 acid ethyl esters	icosapent ethyl	
	LOVAZA (omega-3 acid ethyl esters)	
PCSK-9 INHIBITORS		
REPATHA (evolocumab)	LEQVIO (inclisiran)	
	PRALUENT (alirocumab)	

LIPOTROPICS, STATINS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
STATINS		Minimum Age Limit 10 years: ATORVALIQ Suspension
atorvastatin	ALTOPREV (lovastatin)	
lovastatin	ATORVALIQ (atorvastatin)	Non-Preferred Criteria - Have tried 2 different preferred statin or statin combination agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days
pravastatin	CRESTOR (rosuvastatin)	
rosuvastatin	EZALLOR SPRINKLE (rosuvastatin)	Simvastatin Daily doses ≥ 80 mg require clinical review
simvastatin	FLOLIPID (simvastatin)	
	fluvastatin	
	fluvastatin ER	
	LESCOL XL (fluvastatin)	
	LIPITOR (atorvastatin)	
	LIVALO (pitavastatin)	
	pitavastatin	
	ZOCOR (simvastatin)	
	ZYPITAMAG (pitavastatin)	

STATIN COMBINATIONS		
ezetimibe/simvastatin	amlodipine/atorvastatin	
	CADUET (amlodipine/atorvastatin)	
	VYTORIN (ezetimibe/simvastatin)	
MISCELLANEOUS BRAND/GENERIC		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ALLERGEN EXTRACT IMMUNOTHERAPY		CUMULATIVE quantity limit (per 31 days) • 31 tablets: alprazolam ER Quantity Limit (per 31 days) • 2 kits: epinephrine EVRYSDI MANUAL PA
	GRASTEK	
	ORALAIR	
	RAGWITEK	
EPINEPHRINE		
epinephrine (Mylan)	AUVI-Q (epinephrine)	
	epinephrine (all other manufacturers)	
	EPIPEN (epinephrine)	
	EPIPEN JR (epinephrine)	
	NEFFY (epinephrine)	
MISCELLANEOUS		
alprazolam	alprazolam ER	
hydroxyzine HCL	CAMZYOS (mavacamten)	
hydroxyzine pamoate	CRENESSITY (crinecerfont)	
megestrol	EVRYSDI (risdiplam)	
REVLIMID (lenalidomide)	KORLYM (mifepristone)	
	lenalidomide	
	TRYNGOLZA (olezarsen)	
	VERQUVO (vericiguat)	
	VISTARIL (hydroxyzine pamoate)	
	XANAX, XANAX XR (alprazolam)	
SUBLINGUAL NITROGLYCERIN		
nitroglycerin		
NITROLINGUAL (nitroglycerin)		
NITROSTAT (nitroglycerin)		
MOVEMENT DISORDER AGENTS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
AUSTEDO (deutetrabenazine)	INGREZZA INITIATION PACK (valbenazine)	AUSTEDO and AUSTEDO XR • Documented diagnosis of Huntington's chorea OR • Documented diagnosis of tardive dyskinesia AND • 90 days of therapy with either agent in the past 105 days OR • New starts require clinical review MANUAL PA INGREZZA • Documented diagnosis of Huntington's chorea OR • Documented diagnosis of tardive dyskinesia AND • 90 days of therapy with this agent in the past 105 days OR • New starts require clinical review MANUAL PA
AUSTEDO XR (deutetrabenazine)	XENAZINE (tetrabenazine)	
INGREZZA (valbenazine)		
INGREZZA SPRINKLE (valbenazine)		
tetrabenazine		
MULTIPLE SCLEROSIS AGENTS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BETASERON (interferon beta-1b)	AMPYRA (dalfampridine)	Preferred Agents • Documented diagnosis of multiple sclerosis Non-Preferred Criteria • Documented diagnosis of multiple sclerosis AND • Have tried 2 different preferred agents in the past 6 months OR • 3 claims with the requested agent in the last 105 days KESIMPTA, PONVORY, TASCENSO ODT, and ZEPOSIA • Require clinical review
COPAXONE (glatiramer) 20 mg	AUBAGIO (teriflunomide)	
dalfampridine ER	AVONEX (interferon beta-1a)	
dimethyl fumarate	BAFIERTAM (monomethyl fumarate)	
ingolimod	BRIUMVI (ublituximab-xiyy)	
REBIF (interferon beta-1b)	COPAXONE (glatiramer) 40 mg	
REBIF REBIDOSE (interferon beta-1b)	GILENYA (fingolimod)	
teriflunomide	glatiramer	
TYSABRI (natalizumab)	GLATOPA (glatiramer)	
	KESIMPTA PEN (ofatumumab)	
	MAVENCLAD (cladribine)	

	MAYZENT (siponimod)	MAVENCLAD MANUAL PA MAYZENT MANUAL PA OCREVUS and OCREVUS ZUNOVO MANUAL PA
	OCREVUS (ocrelizumab)	
	OCREVUS ZUNOVO (ocrelizumab/hyaluronidase-ocsq)	
	PLEGRIDY (peginterferon beta-1a)	
	PONVORY (ponesimod)	
	TASCENSO ODT (fingolimod)	
	TECFIDERA (dimethyl fumarate)	
	VUMERITY (diroximel fumarate)	
	ZEPOSIA (ozanimod)	

MUSCULAR DYSTROPHY AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
EMFLAZA (deflazacort)	AGAMREE (vamorolone)	AGAMREE MANUAL PA ELEVIDYS MANUAL PA EMFLAZA MANUAL PA EXONDYS MANUAL PA VILTEPSO MANUAL PA VYONDYS MANUAL PA
	AMONDYS-45 (casimersen)	
	deflazacort	
	DUVYZAT (givinostat)	
	ELEVIDYS (delandistrogene moxeparvovec-rokl)	
	EXONDYS-51 (eteplirsen)	
	VILTEPSO (viltolarsen)	
	VYONDYS-53 (golodirsen)	

NSAIDS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
COX II SELECTIVE		Quantity Limit (per 31 days) • 20 tablets: ketorolac tablets ELYXYB • Requires clinical review
meloxicam	CELEBREX (celecoxib)	
	celecoxib	
	ELYXYB (celecoxib)	Non-Preferred Criteria COX II Selective • No history of a contraindicated GI disorder or coagulation disorder AND • Documented diagnosis of Osteoarthritis, Rheumatoid Arthritis, Familial Adenomatous Polyposis, or Ankylosing Spondylitis AND • Have tried 1 preferred COX-II selective agent OR • 90 days of therapy with the requested agent in the past 105 days Non-Preferred Criteria Non-Selective & Combinations • No history of a contraindicated GI disorder or coagulation disorder AND • Have tried 2 different preferred non-selective agents in the past 6 months
NON-SELECTIVE		
diclofenac sodium	DAYPRO (oxaprozin)	
diclofenac sodium ER	diclofenac potassium	
EC-naproxen DR 500 mg tablet	DOLOBID (diflunisal)	
etodolac tablet	etodolac capsule, etodolac ER	
flurbiprofen	FELDENE (piroxicam)	
ibuprofen	fenoprofen	
indomethacin capsule	indomethacin ER, indomethacin suppository	
ketoprofen	ketoprofen	
ketorolac	kiprofen	
nabumetone	LOFENA (diclofenac potassium)	
naproxen 250 mg, 500 mg	meclofenamate	
piroxicam	mefenamic acid	
sulindac	NALFON (fenoprofen)	
	NAPRELAN (naproxen)	
	NAPROSYN 375 mg (naproxen)	
	naproxen 375 mg, naproxen CR 375 mg, naproxen ER 500 mg	
	oxaprozin	
	RELAFEN DS (nabumetone)	
	TOLECTIN 600 mg (tolmetin)	
	tolmetin	
NSAID/GI PROTECTANT COMBINATIONS		
	ARTHROTEC 50 mg, 75 mg (diclofenac/misoprostol)	
	diclofenac/misoprostol	
	ibuprofen/famotidine	
	naproxen/esomeprazole	
	VIMOVO (naproxen/esomeprazole)	

OPHTHALMIC AGENTS		
-------------------	--	--

PREFERRED AGENTS		NON-PREFERRED AGENTS	PA CRITERIA	
ANTIBIOTICS			Minimum Age Limit • 16 years: RESTASIS • 17 years: XIIDRA • 18 years: CEQUA, MIEBO, TRYPTYR, VEVYE Quantity Limit (per 31 days) • 2 mL: VEVYE • 3 mL: MIEBO • 5.5 mL: RESTASIS Multidose • 60 units: CEQUA, RESTASIS Droperette, TRYPTYR, XIIDRA Non-Preferred Criteria • Anti-Inflammatory Agents ◦ Have tried 2 different preferred agents in the past 6 months • Dry Eye Agents ◦ History of 1 claim for both RESTASIS Droperette and XIIDRA in the past 6 months EYSUVIS • Require clinical review MIEBO • Requires clinical review RESTASIS Multidose • Require clinical review TRYPTYR • Requires clinical review TYRVAYA • Requires clinical review VEVYE • Requires clinical review	
bacitracin/polymyxin		AZASITE (azithromycin)		
ciprofloxacin		bacitracin		
erythromycin		BESIVANCE (besifloxacin)		
gentamicin		CILOXAN (ciprofloxacin)		
moxifloxacin		gatifloxacin		
ofloxacin		NATACYN (natamycin0		
polymyxin B/trimethoprim		neomycin/bacitracin/polymyxin		
tobramycin		OCUFLOX (ofloxacin)		
		sulfacetamide		
		TOBREX (tobramycin)		
		VIGAMOX (moxifloxacin)		
ANTIBIOTIC-STEROID COMBINATIONS				
BLEPHAMIDE S.O.P. (sulfacetamide/prednisolone)		MAXITROL (neomycin/polymyxin/dexamethasone)		
neomycin/bacitracin/polymyxin/hydrocortisone		neomycin/polymyxin/gramicidin		
neomycin/polymyxin/dexamethasone		TOBRADEX ST (tobramycin/dexamethasone)		
PRED-G (gentamicin/prednisolone)				
sulfacetamide/prednisolone				
TOBRADEX (tobramycin/dexamethasone)				
tobramycin/dexamethasone				
ZYLET (tobramycin/loteprednol)				
ANTI-INFLAMMATORY AGENTS ^{DUR+}				
dexamethasone		ACULAR, ACULAR LS (ketorolac)		
diclofenac sodium		ACUVAIL (ketorolac)		
difluprednate		bromfenac		
FLAREX (fluorometholone)		BROMSITE (bromfenac)		
fluorometholone		DUREZOL (difluprednate)		
flurbiprofen		FML (fluorometholone)		
FML FORTE (fluorometholone)		ILEVRO (nepafenac)		
ketorolac		INVELTYS (loteprednol)		
MAXIDEX (dexamethasone)		LOTEMAX, LOTEMAX SM (loteprednol)		
PRED MILD (prednisolone)		loteprednol		
prednisolone acetate		NEVANAC (nepafenac)		
prednisolone sodium phosphate		PRED FORTE (prednisolone)		
		PROLENSA (bromfenac)		
DRY EYE AGENTS				
RESTASIS Droperette (cyclosporine)		CEQUA (cyclosporine)		
XIIDRA (lifitegrast)		cyclosporine		
		EYSUVIS (loteprednol)		
		MIEBO (perfluorohexyloactane)		
		RESTASIS Multidose (cyclosporine)		
		TYRVAYA (varenicline)		
		VEVYE (cyclosporine)		
OPHTHALMIC, GLAUCOMA AGENTS				
PREFERRED AGENTS		NON-PREFERRED AGENTS		PA CRITERIA
BETA BLOCKERS			Minimum Age Limit • 18 years: IYUZEH Non-Preferred Criteria • Have tried 2 different preferred agents in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days	
BETIMOL (timolol)		betaxolol		
carteolol		BETOPTIC S (betaxolol)		
ISTALOL (timolol)		timolol droperette, daily drop, gel		
levobunolol		TIMOPTIC; TIMOPTIC OCUDOSE, XE (timolol)		
timolol drops 0.25%, 0.5%				
CARBONIC ANHYDRASE INHIBITORS				
dorzolamide		AZOPT (brinzolamide)		
		brinzolamide		
COMBINATION AGENTS				
COMBIGAN (brimonidine/timolol)		brimonidine/timolol		

dorzolamide/timolol	COSOPT (dorzolamide/timolol)
SIMBRINZA (brinzolamide/brimonidine)	dorzolamide/timolol PF
PARASYMPATHOMIMETICS	
pilocarpine	PHOSPHOLINE IODIDE (echothiophate iodide)
PROSTAGLANDIN ANALOGS	
latanoprost	bimatoprost
	IYUZEH (latanoprost)
	LUMIGAN (bimatoprost)
	tafluprost
	TRAVATAN Z (travoprost)
	travoprost
	VYZULTA (latanoprostene bunod)
	XALATAN (latanoprost)
	XELPROS (latanoprost)
	ZIOPTAN (tafluprost)
RHO KINASE INHIBITORS/COMBINATIONS	
RHOPRESSA (netarsudil)	
ROCKLATAN (netarsudil/latanoprost)	
SYMPATHOMIMETICS	
ALPHAGAN P (brimonidine)	brimonidine 0.1%, 0.15%
brimonidine 0.2%	

OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ALREX (loteprednol)	ALOCRIL (nedocromil)	Non-Preferred Criteria - Have tried 2 different preferred agents in the past 6 months VERKAZIA - Requires clinical review
azelastine	ALOMIDE (lodoxamide)	
cromolyn	bepotastine	
ketotifen ^{OTC}	BEPREVE (bepotastine)	
olopatadine	epinastine	
ZADITOR (ketotifen)	LASTACFT (alcaftadine)	
	VERKAZIA (cyclosporine)	
	ZERViate (cetirizine)	

OPIATE DEPENDENCE TREATMENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
DEPENDENCE		Buprenorphine/naloxone provider summary found here SUBLOCADE MANUAL PA VIVITROL MANUAL PA
buprenorphine/naloxone SL tablet ^{DUR+}	BRIXADI (buprenorphine)	
naltrexone	buprenorphine ^{DUR+}	
SUBOXONE (buprenorphine/naloxone) ^{DUR+}	buprenorphine/naloxone film ^{DUR+}	
	lofexidine	
	LUCEMYRA (lofexidine)	
	SUBLOCADE (buprenorphine)	
	VIVITROL (naltrexone)	
	ZUBSOLV (buprenorphine/naloxone)	
TREATMENT		
KLOXXADO (naloxone)	LIFEMS NALOXONE (naloxone convenience kit)	
naloxone		
NARCAN (naloxone)		
OPVEE (nalmefene)		
REXTOVY (naloxone)		
ZIMHI (naloxone)		

OTIC ANTIBIOTICS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CIPRO HC (ciprofloxacin/hydrocortisone)	ciprofloxacin	Maximum Age Limit 9 years: CIPRO HC Ciprofloxacin/Dexamethasone Suspension Criteria - Age ≥ 6 months AND
CORTISPORIN-TC (neomycin/colistin/hydrocortisone)	ciprofloxacin/fluocinolone	
fluocinolone	ciprofloxacin/dexamethasone	
neomycin/polymyxin/hydrocortisone	DERMOTIC (fluocinolone)	

	FLAC OTIC OIL (fluocinolone)	• Experiencing otorrhea secondary to recent, post-tympanostomy tube placement AND • Continued otorrhea after 10 days of otic treatment with ciprofloxacin ophthalmic solution and dexamethasone ophthalmic suspension
	hydrocortisone/acetic acid	
	OTOVEL (ciprofloxacin/fluocinolone)	
PANCREATIC ENZYMES		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CREON (lipase/protease/amylase)	PERTZYE (lipase/protease/amylase)	Non-Preferred Criteria • Have tried 2 different preferred agents in the past 6 months
ZENPEP (lipase/protease/amylase)	VIOKACE (lipase/protease/amylase)	
PARATHYROID AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
calcitriol	doxercalciferol	
cinacalcet	RAYALDEE (calcifediol)	
ergocalciferol	ROCALTROL (calcitriol)	
paricalcitol	SENSIPAR (cinacalcet)	
ZEMPLAR (paricalcitol)	YORVIPATH (palopegteriparatide)	
PHOSPHATE BINDERS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
calcium acetate	AURYXIA (ferric citrate)	
CALPHRON (calcium acetate)	FOSRENOL (lanthanum)	
sevelamer carbonate tablet	lanthanum	
	MAGNEBIND (calcium carbonate/magnesium)	
	REVELA (sevelamer)	
	sevelamer carbonate packet, sevelamer HCl	
	VELPHORO (sucroferric oxyhydroxide)	
	XPHOZAH (tenapanor)	
PLATELET AGGREGATION INHIBITORS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
aspirin/dipyridamole	EFFIENT (prasugrel)	Non-Preferred Criteria • Documented diagnosis AND • Have tried 2 different preferred agents in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days
BRILINTA (ticagrelor)	PLAVIX (clopidogrel)	
cilostazol	ticagrelor ^{NR}	
clopidogrel		
dipyridamole		
pentoxifylline		
prasugrel		ZONTIVITY MANUAL PA
PLATELET STIMULATING AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
NPLATE (romiplostim)	ALVAIZ (eltrombopag)	
PROMACTA (eltrombopag) tablet	DOPTELET (avatrombopag)	
	MULPLETA (lusutrombopag)	
	PROMACTA (eltrombopag) packet	
	TAVALISSE (fostamatinib)	
POTASSIUM REMOVING AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
LOKELMA (sodium zirconium cyclosilicate)	KIONEX (sodium polystyrene sulfonate)	
SPS (sodium polystyrene sulfonate) suspension	sodium polystyrene sulfonate	
	SPS (sodium polystyrene sulfonate) enema	
	VELTASSA (patiromer calcium sorbitex)	
PRENATAL VITAMINS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CLASSIC PRENATAL	All prenatal vitamins are non-preferred except for those specifically indicated as preferred.	
COMPLETE NATAL DHA		
COMPLETENATE		
M-NATAL PLUS		
NIVA-PLUS		
PRENATAL PLUS VITAMIN-MINERAL		
PNV 72, 95, 124, and 137 / IRON / FOLIC ACID		
SE-NATAL-19		
		List of Preferred NDC's for Prenatal Vitamins can be found here

STUART ONE		
THRIVITE RX		
TRICARE		
TRINATAL RX 1		
WESNATAL DHA COMPLETE		
WESTAB PLUS		

PSEUDOBULBAR AFFECT AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	NUDEXTA (dextromethorphan/quinidine)	Non-Preferred Criteria - Documented diagnosis of pseudobulbar affect disorder OR 90 days of therapy with NUDEXTA in the past 105 days

PULMONARY ANTIHYPERTENSIVE AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ACTIVIN SIGNALING INHIBITORS		Minimum Age Limit • 18 years: ADEMPAS, OPSYNVI, TADLIQ
	WINREVAIR (sotatercept-csrk)	
COMBINATION AGENTS		Maximum Age Limit • 12 years: REVATIO suspension
	OPSYNVI (macitentan/tadalafil)	
ENDOTHELIN RECEPTOR ANTAGONISTS		Preferred Criteria • PAH Agents ○ Documented diagnosis of pulmonary hypertension
ambrisentan	OPSUMIT (macitentan)	
bosentan	TRACLEER (bosentan)	
LETAIRIS (ambrisentan)	TRYVIO (aprocitentan)	
PDE5 INHIBITORS		• Sildenafil tablets ○ ≤ 1 year of age and documented diagnosis of pulmonary hypertension, patent ductus arteriosus, or persistent fetal circulation OR ○ ≥ 1 year of age and documented diagnosis of pulmonary hypertension OR ○ 90 days of therapy with the requested agent in the past 105 days
sildenafil (generic REVATIO) tablet, suspension	ADCIRCA (tadalafil)	
tadalafil	ALYQ (tadalafil)	
	REVATIO (sildenafil)	
	TADLIQ (tadalafil)	
PROSTACYCLINS		• Sildenafil suspension • < 12 years of age AND • Documented diagnosis of pulmonary hypertension, patent ductus arteriosus, or persistent fetal circulation, or a history of a heart transplant OR • 90 days stable therapy with sildenafil suspension in the past 105 days
	ORENITRAM ER (treprostinil)	
	ORENITRAM TITRATION PAK (treprostinil)	
	TYVASO (treprostinil)	
	VENTAVIS (iloprost)	
SELECTIVE PROSTACYCLINE RECEPTOR AGONISTS		Non-Preferred Criteria • Documented diagnosis of pulmonary hypertension AND • Have tried 1 preferred PAH agent in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days
	UPTRAVI (selexipag)	
SOLUABLE GUANYLATE CYCLASE STIMULATORS		OPSUMIT, OPSYNVI, ORENITRAM ER, TYVASO, and VENTAVIS • Require clinical review
	ADEMPAS (riociguat)	

ADEMPAS - Documented diagnosis of persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) or pulmonary arterial hypertension (WHO Group 1) AND - Have tried 1 preferred PAH agent in the past 6 months OR 90 days of therapy with ADEMPAS in the past 105 days	TADLIQ - Documented diagnosis of pulmonary hypertension AND - Have tried preferred sildenafil suspension in the past 6 months OR 90 days of therapy with TADLIQ in the past 105 days
	UPTRAVI - Documented diagnosis of pulmonary hypertension AND - Have tried 1 preferred endothelin receptor antagonist in the past 6 months AND - Have tried 1 preferred PDE5 inhibitor in the past 6 months OR 90 days of therapy with UPTRAVI in the past 105 days

ROSACEA TREATMENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
metronidazole	AVAR (sulfacetamide sodium/sulfur)	Note: Topical Sulfonamides used for Rosacea will require a manual PA for age > 21 years.
	AVAR LS (sulfacetamide sodium/sulfur)	

	AVAR-E (sulfacetamide sodium/sulfur)	Other labeled indications are limited to < 21 years.
	BP 10-1 (sulfacetamide sodium/sulfur)	
	brimonidine	
	EPSOLAY (benzoyl peroxide)	
	FINACEA (azelaic acid)	
	METROCREAM (metronidazole)	
	METROGEL (metronidazole)	
	MIRVASO (brimonidine)	
	NORITATE (metronidazole)	
	OVACE (sulfacetamide sodium)	
	OVACE PLUS (sulfacetamide sodium)	
	RHOFADE (oxymetazoline)	
	ROSADAN (metronidazole)	
	ROSULA (sulfacetamide sodium/sulfur)	
	sodium sulfacetamide	
	sodium sulfacetamide/sulfur	
	SOOLANTRA (ivermectin)	
	SUMADAN (sulfacetamide sodium/sulfur)	
	SUMADAN XLT (sulfacetamide sodium/sulfur/avob)	
	SUMAXIN (sulfacetamide sodium/sulfur)	
	SUMAXIN CP (sulfacetamide sodium/sulfur)	
	SUMAXIN TS (sulfacetamide sodium/sulfur)	

SEDATIVE HYPNOTIC AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BENZODIAZEPINES DUR+		MS DOM Opioid Initiative Criteria details found here - Concomitant use of Opioids and Benzodiazepines Maximum Age Limit 64 years: zolpidem 7.5 mg, 10 mg, and 12.5 mg Gender and Dose Limit Female: AMBIEN 5 mg, AMBIEN CR 6.25 mg, INTERMEZZO 1.75 mg Male: all strengths of zolpidem Non-Preferred Criteria - Have tried 2 different preferred agents in the past 6 months HETLIOZ capsules - Age 18 years or older AND - Documented diagnosis of circadian rhythm sleep disorder - OR - Age 16 years and older AND - Documented diagnosis of Smith-Magenis syndrome HETLIOZ liquid - Age 3-15 years AND - Documented diagnosis of Smith-Magenis syndrome Note: - Single-source benzodiazepines and barbiturates are NOT covered. - PA s will NOT be issued for these drugs. See below for additional PA Criteria/DUR+ Rules
estazolam	flurazepam	
temazepam 15 mg, 30 mg capsule	HALCION (triazolam)	
	quazepam	
	RESTORIL (temazepam)	
	temazepam 7.5 mg, 22.5 mg capsule	
	triazolam	
OTHERS DUR+		
eszopiclone	AMBIEN (zolpidem)	
ramelteon	AMBIEN CR (zolpidem)	
zaleplon	BELSOMRA (suvorexant)	
zolpidem tablet	DAYVIGO (lemborexant)	
	doxepin	
	EDULAR (zolpidem)	
	HETLIOZ LQ (tasimelteon)	
	LUNESTA (eszopiclone)	
	QUVIVIQ (daridorexant)	
	ROZEREM (ramelteon)	
	tasimelteon	
	zolpidem capsule	
	zolpidem sublingual tablet	
	zolpidem ER	

CUMULATIVE Quantity Limit Benzodiazepines

- 31 units/31 days:** Quantity limit per rolling days for all strengths. DUR+ will allow an early refill override for one dose or therapy change per year.

CUMULATIVE Quantity Limit Triazolam

- 10 units/31 days:** Quantity limit per rolling days for all strengths.
- 60 units/365 days:** Quantity limit per rolling days for all strengths.

CUMULATIVE Quantity Limit Non-Benzodiazepines

- **31 units/31 days:** Quantity limit per rolling days for all strengths. DUR+ will allow an early refill override for one dose or therapy change per year.

CUMULATIVE Quantity Limit HETLIOZ LQ

- **1 bottle (48 mL or 158 mL):** Quantity limit per rolling days for all strengths. DUR+ will allow an early refill override for one dose or therapy change per year.

CUMULATIVE Quantity Limit ZOLPIMIST

- **1 canister/31 days:** male; Quantity limit per rolling days for all strengths. DUR+ will allow an early refill override for one dose or therapy change per year.
- **1 canister/62 days:** female; Quantity limit per rolling days for all strengths. DUR+ will allow an early refill override for one dose or therapy change per year.

SELECT CONTRACEPTIVE PRODUCTS

PREFERRED AGENTS		NON-PREFERRED AGENTS	PA CRITERIA
INJECTABLE CONTRACEPTIVES			Non-Preferred Criteria • 1 claim with the requested agent in the past 105 days
medroxyprogesterone	DEPO-PROVERA (medroxyprogesterone)		
INTRAVAGINAL CONTRACEPTIVES			
ANNOVERA (segesterone/ethinyl estradiol)	PHEXXI (lactic acid/citric acid/potassium bitartrate)		
ENILLORING (etonogestrel/ethinyl estradiol)			
NUVARING (etonogestrel/ethinyl estradiol)			
ORAL CONTRACEPTIVES ^{DUR+}			
All oral contraceptives are preferred except for those specifically indicated as non-preferred.	AMETHIA (levonorgestrel/ethinyl estradiol)		
	AMETHYST (levonorgestrel/ethinyl estradiol)		
	BALCOLTRA (levonorgestrel/ethinyl estradiol)		
	BEYAZ (drospirenone/ethinyl estradiol/levomefolate)		
	CAMRESE (levonorgestrel/ethinyl estradiol)		
	CAMRESE LO (levonorgestrel/ethinyl estradiol)		
	JOLESSA (levonorgestrel/ethinyl estradiol)		
	LO LOESTRIN FE (norethindrone/ethinyl estradiol/iron)		
	LOESTRIN (norethindrone/ethinyl estradiol)		
	LOESTRIN FE (norethindrone/ethinyl estradiol/iron)		
	MINZOYA (levonorgestrel/ethinyl estradiol/iron)		
	NATAZIA (estradiol valerate/dienogest)		
	NEXTSTELLIS (drospirenone/estetrol)		
	OCELLA (ethinyl estradiol/drospirenone)		
	SAFYRAL (drospirenone/ethinyl estradiol/levomefolate)		
	SIMPESSSE (levonorgestrel/ethinyl estradiol)		
	TAYTULLA (norethindrone/ethinyl estradiol/iron)		
	TYDEMY (drospirenone/ethinyl estradiol/levomefolate)		
	YASMIN (ethinyl estradiol/drospirenone)		
	YAZ (ethinyl estradiol/drospirenone)		
TRANSDERMAL CONTRACEPTIVES			
XULANE (norgestromin/ethinyl estradiol)	norgestromin/ethinyl estradiol		
	TWIRLA (levonorgestrel/ethinyl estradiol)		
	ZAFEMY (norgestromin/ethinyl estradiol)		

SICKLE CELL AGENTS

PREFERRED AGENTS		NON-PREFERRED AGENTS	PA CRITERIA
DROXIA (hydroxyurea)		ADAKVEO (crizanlizumab-tmca)	ENDARI MANUAL PA
hydroxyurea		CASGEVY (exagamglogene autotemcel)	
		ENDARI (glutamine)	
		HYDREA (hydroxyurea)	
		l-glutamine	
		LYFGENIA (lovotibeglogene autotemcel)	

		SIKLOS (hydroxyurea)		
SKELETAL MUSCLE RELAXANTS ^{DUR+}				
PREFERRED AGENTS		NON-PREFERRED AGENTS	PA CRITERIA	
baclofen 5 mg, 10 mg, 20 mg tablet		AMRIX (cyclobenzaprine)	Quantity Limit 84 tablets/180 days: carisoprodol Non-Preferred Criteria - Documented diagnosis of an approvable indication AND - Have tried 2 different preferred agents in the past 6 months Baclofen granules, solution, and suspension - Require clinical review. Carisoprodol - Documented diagnosis of acute musculoskeletal condition AND - No history with meprobamate in the past 105 days AND - History of 1 claim for cyclobenzaprine in the past 21 days Carisoprodol with codeine - Requires clinical review. Metaxalone 640 mg and TANLOR - Requires clinical review	
chlorzoxazone		baclofen 15 mg tablet		
cyclobenzaprine 5 mg, 10 mg tablet		baclofen suspension		
methocarbamol		carisoprodol		
tizanidine tablet		carisoprodol/aspirin		
		cyclobenzaprine 7.5 mg tablet		
		cyclobenzaprine ER		
		DANTRIUM (dantrolene)		
		dantrolene		
		FEXMID (cyclobenzaprine)		
		FLEQSUVY (baclofen)		
		LORZONE (chlorzoxazone)		
		LYVISPAH (baclofen)		
		metaxalone		
		NORGESIC (orphenadrine/aspirin/caffeine)		
		NORGESIC FORTE (orphenadrine/aspirin/caffeine)		
		orphenadrine		
		orphenadrine/aspirin/caffeine		
		ORPHENGESIC FORTE (orphenadrine/aspirin/caffeine)		
		SOMA (carisoprodol)		
		TANLOR (methocarbamol)		
		tizanidine capsule		
		ZANAFLEX (tizanidine)		
SMOKING DETERRENTS				
PREFERRED AGENTS		NON-PREFERRED AGENTS	PA CRITERIA	
NICOTINE TYPE			Minimum Age Limit 18 years: CHANTIX Quantity Limit 336 tablets/year: CHANTIX 0.5 mg tabs, 1 mg tabs, and continuing pack 2 treatment courses/year: CHANTIX Starter Pack	
nicotine gum ^{OTC}		NICOTROL INHALER CARTRIDGE		
nicotine lozenge ^{OTC}		NICOTROL NASAL SPRAY		
nicotine patch ^{OTC}				
NON-NICOTINE TYPE				
bupropion SR				
CHANTIX (varenicline)				
varenicline				
STEROIDS (TOPICAL)				
PREFERRED AGENTS		NON-PREFERRED AGENTS	PA CRITERIA	
LOW POTENCY			Non-Preferred Criteria Low Potency - Have tried 2 different preferred low potency agents in the past 6 months Medium Potency - Have tried 2 different preferred medium potency agents in the past 6 months High Potency - Have tried 2 different preferred high potency agents in the past 6 months Very High Potency - Have tried 2 different preferred very high potency agents in the past 6 months Clobetasol 0.025% - Requires clinical review.	
alclometasone		fluocinolone		
DERMA-SMOOTH-ES (fluocinolone)		hydrocortisone lotion		
desonide		HYDROXYM (hydrocortisone)		
hydrocortisone cream, ointment, solution		PROCTOCORT (hydrocortisone)		
MEDIUM POTENCY				
fluticasone		BESER (fluticasone)		
mometasone		CAPEX (fluocinolone)		
PANDEL (hydrocortisone probutate)		clocortolone		
prednicarbate cream		CLODERM (clocortolone)		
		flurandrenolide		
		fluticasone lotion		
		LOCOID (hydrocortisone butyrate)		
		prednicarbate ointment		
		SYNALAR (fluocinolone)		
HIGH POTENCY				
betamethasone dipropionate cream, lotion		amcinonide		
betamethasone dipropionate augmented		betamethasone dipropionate ointment		

betamethasone valerate	desoximetasone
fluocinolone	diflorasone
fluocinonide	Halcinonide
fluocinonide-E	HALOG (halcinonide)
triamcinolone cream, ointment, lotion	KENALOG (triamcinolone)
	TOPICORT (desoximetasone)
	triamcinolone spray
	VANOS (fluocinonide)
VERY HIGH POTENCY	
clobetasol cream, foam, gel, ointment, shampoo, solution	APEXICON E (diflorasone)
clobetasol-E	BRYHALI (halobetasol)
halobetasol	clobetasol emulsion
	clobetasol 0.025% cream
	CLOBEX (clobetasol)
	CLODAN (clobetasol)
	DIPROLENE (betamethasone)
	halobetasol
	IMPEKLO (clobetasol)
	IMPOYZ (clobetasol) 0.025% cream
	LEXETTE (halobetasol)
	OLUX (clobetasol)
	TEMOVATE (clobetasol)
	TOVET (clobetasol)
	ULTRAVATE (halobetasol)

STIMULANTS AND RELATED AGENTS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
SHORT-ACTING		Minimum Age Limit • 3 years: ADDERALL, EVEKEO, PROCENTRA, ZENZEDI • 6 years: ADDERALL XR, ADHANSIA XR, ADZENYS ER SUSPENSION, ADZENYS XR ODT, APTENSIO XR, atomoxetine, AZSTARYS, clonidine ER, CONCERTA ER, COTEMPLA XR ODT, DAYTRANA, DESOXYN, DEXEDRINE, DYANAVEL XR, EVEKEO ODT, FOCALIN, FOCALIN XR, JORNAY PM, METADATE CD, METHYLIN, ONYDA XR, QELBREE, QUILLICHEW, QUILLIVANT XR, RELEXII ER, RITALIN LA, VYVANSE, XELSTRYM • 7 years: XYREM • 13 years: MYDAYIS • 16 years: modafinil • 18 years: armodafinil, SUNOSI, WAKIX Maximum Age Limit • 18 years: clonidine ER, COTEMPLA XR ODT, DAYTRANA, EVEKEO ODT, guanfacine ER Quantity Limit Stimulants (per 31 days) • 31 tablets: ADDERALL XR, ADHANSIA XR, ADZENYS XR ODT, APTENSIO XR, AZSTARYS, CONCERTA ER 18, 27, & 54 mg, COTEMPLA XR-ODT 8.6 mg, DAYTRANA, DEXEDRINE Spansule, DYANAVEL XR Tablet, FOCALIN XR, JORNAY PM, METADATE CD, METHYLIN ER, MYDAYIS 37.5 mg & 50 mg, QUILLICHEW, RELEXII ER, RITALIN LA & SR, VYVANSE, XELSTRYM • 62 tablets: ADDERALL, CONCERTA ER 36 mg, COTEMPLA XR-ODT 17.3 & 25.9 mg, DESOXYN, EVEKEO, FOCALIN, METHYLIN, RITALIN, ZENZEDI • 248 mL: DYANAVEL XR Suspension • 310 mL: METHYLIN, PROCENTRA • 372 mL: QUILLIVANT XR Quantity Limit Narcolepsy (per 31 days) • 31 tablets: armodafinil 150, 200 & 250 mg, modafinil 200 mg, SUNOSI • 46.5 tablets: modafinil 100 mg • 62 tablets: armodafinil 50 mg, WAKIX Quantity Limit Non-Stimulants (per 31 days) • 31 tablets: atomoxetine, guanfacine ER, QELBREE 100 mg • 62 tablets: QELBREE 150 mg and 200 mg
dexmethylphenidate	ADDERALL (dextroamphetamine/amphetamine)	
dextroamphetamine	amphetamine	
dextroamphetamine/amphetamine	EVEKEO (amphetamine)	
Methylphenidate tablet	dextroamphetamine solution	
PROCENTRA (dextroamphetamine)	EVEKEO ODT (amphetamine)	
	FOCALIN (dexmethylphenidate)	
	methamphetamine	
	METHYLN (methylphenidate)	
	Methylphenidate chewable tablet	
	RITALIN (methylphenidate)	
	ZENZEDI (dextroamphetamine)	
LONG-ACTING		
ADDERALL XR (dextroamphetamine/amphetamine)	ADZENYS XR ODT (amphetamine)	
CONCERTA (methylphenidate)	APTENSIO XR (methylphenidate)	
dexmethylphenidate ER	AZSTARYS (serdexmethylphenidate/dexmethylphenidate)	
dextroamphetamine ER	COTEMPLA XR ODT (methylphenidate)	
dextroamphetamine/amphetamine ER (generic ADDERALL XR)	DAYTRANA (methylphenidate)	
DYANAVEL XR (amphetamine) suspension	DEXEDRINE (dextroamphetamine)	
lisdexamfetamine	dextroamphetamine/amphetamine ER (generic MYDAYIS ER)	
methylphenidate CD	DYANAVEL XR (amphetamine) tablets	
methylphenidate ER tablet	FOCALIN XR (dexmethylphenidate)	
methylphenidate LA	JORNAY PM (methylphenidate)	
QUILLICHEW ER (methylphenidate)	methylphenidate patch	
QUILLIVANT XR (methylphenidate)	methylphenidate ER capsule	
VYVANSE (lisdexamfetamine) capsules	MYDAYIS (dextroamphetamine/amphetamine)	
	RELEXII (methylphenidate)	
	RITALIN LA (methylphenidate)	

	VYVANSE (lisdexamfetamine) chewable tablets	• 124 tablets: clonidine ER • 1 bottle (30 mL or 60 mL): ONYDA XR Suspension
	XELSTRYM (dextroamphetamine)	
NARCOLEPSY		
armodafinil	NUVIGIL (armodafinil)	
modafinil	PROVIGIL (modafinil)	
SUNOSI (solriamfetol)	sodium oxybate	
XYREM (sodium oxybate)	WAKIX (pitolisant)	
	XYWAV (calcium/magnesium/potassium/sodium oxybate)	
NON-STIMULANTS		
atomoxetine	INTUNIV (guanfacine)	
clonidine ER (generic Kapvay only)	ONYDA XR (clonidine)	
guanfacine ER	STRATTERA (atomoxetine)	
QELBREE (viloxazine)		

Non-Preferred Short Acting Criteria ADD/ADHD • Documented diagnosis of ADD/ADHD AND • Have tried 2 different preferred Short Acting agents in the past 6 months OR • 1 claim for a 30-day supply with the requested agent in the past 105 days Narcolepsy: ADDERALL, EVEKEO, METHYLIN, PROCENTRA, RITALIN, ZENZEDI • Documented diagnosis of narcolepsy AND • 30 days of therapy with preferred modafinil or armodafinil in the past 6 months AND • 1 preferred agent indicated for narcolepsy in the past 6 months OR • Have tried 1 claim for a 30-day supply with the requested agent in the past 105 days	Non-Preferred Long Acting Criteria ADD/ADHD • Documented diagnosis of ADD/ADHD AND • Have tried 2 different preferred Long-Acting agents in the past 6 months OR • 1 claim for a 30-day supply with the requested agent in the past 105 days Narcolepsy: ADDERALL XR, APTENSIO XR, CONCERTA ER, DEXEDRINE, METADATE CD, METHYLIN ER, MYDAYIS, NUVIGIL, PROVIGIL, QUILLICHEW, QUILLIVANT XR, RITALIN LA • Documented diagnosis of narcolepsy AND • 30 days of therapy with preferred modafinil or armodafinil in the past 6 months AND • 1 different preferred agent indicated for narcolepsy in the past 6 months OR • 1 claim for a 30-day supply with the requested agent in the past 105 days
--	---

Armodafinil • Documented diagnosis of narcolepsy, obstructive sleep apnea, shift work sleep disorder, or bipolar depression Atomoxetine • Age ≥ 21 years AND • Documented diagnosis of ADD/ADHD Clonidine ER • Documented diagnosis of ADD/ADHD Guanfacine ER • Documented diagnosis of ADD/ADHD JORNAY PM • Diagnosis of ADD/ADHD AND • History of 84 days of therapy (each) with 2 different preferred LA methylphenidate products in the past 12 months AND • History of 84 days of therapy with 1 preferred non-methylphenidate LA stimulant in the past 12 months OR • History of 84 days of therapy with JORNAY PM in the past 105 days Modafinil	QELBREE • Documented diagnosis of ADD/ADHD AND • 30 days of therapy with a preferred ADHD agent in the past 105 days OR • 30 days of therapy with QELBREE in the past 105 days SUNOSI • Documented diagnosis of narcolepsy or obstructive sleep apnea AND • 30 days of therapy with preferred modafinil or armodafinil in the past 6 months VYVANSE • Documented diagnosis of binge eating disorder or ADD/ADHD • 90 days of therapy with Vyvanse in the past 90 days VYVANSE chewable • Requires clinical review WAKIX • Requires clinical review XYREM • Diagnosis of narcolepsy or excessive daytime sleepiness OR • 30 days of therapy with this agent in the past 105 days XYWAV • Requires clinical review
--	--

Documented diagnosis of narcolepsy, obstructive sleep apnea, shift work sleep disorder, depression, sleep deprivation or Steinert Myotonic Dystrophy Syndrome		
ONYDA XR		
Requires clinical review		

TETRACYCLINES ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
doxycycline hyclate	demeclocycline	Non-Preferred Agents - Have tried 2 different preferred agents in the past 6 months Demeclocycline - Documented diagnosis of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) will allow for automatic approval ORACEA - Requires clinical review
doxycycline monohydrate capsule	DORYX (doxycycline hyclate)	
minocycline capsule	DORYX MPC (doxycycline hyclate)	
tetracycline capsule	doxycycline hyclate DR	
	doxycycline IR/DR	
	doxycycline monohydrate suspension, tablet	
	LYMEPAK (doxycycline hyclate)	
	MINOCIN (minocycline)	
	minocycline tablet	
	minocycline ER	
	MINOLIRA ER (minocycline)	
	MORGIDOX (doxycycline hyclate)	
	NUZYRA (omadacycline)	
	ORACEA (doxycycline monohydrate)	
	SOLODYN (minocycline)	
	tetracycline tablet	

ULCERATIVE COLITIS & CROHN'S AGENTS ^{DUR+} *See Cytokine & CAM Antagonists Class for Additional Agents*			
PREFERRED AGENTS		NON-PREFERRED AGENTS	PA CRITERIA
ORAL			Non-Preferred Criteria • Documented diagnosis of Ulcerative Colitis AND • Have tried 2 different preferred agents in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days VELSIPITY • Requires clinical review
APRISO (mesalamine)	AZULFIDINE (sulfasalazine)		
balsalazide	COLAZAL (balsalazide)		
budesonide	DELZICOL (mesalamine)		
PENTASA (mesalamine)	DIPENTUM (olsalazine)		
sulfasalazine	LIALDA (mesalamine)		
sulfasalazine DR	mesalamine		
UCERIS (budesonide)	mesalamine DR, mesalamine ER		
	VELSIPITY (etrasimod)		
RECTAL			
mesalamine suppository	budesonide		
	CANASA (mesalamine)		
	mesalamine enema		
	ROWASA (mesalamine)		
	SFROWASA (mesalamine)		
	UCERIS (budesonide)		

UREA CYCLE DISORDER AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CARBAGLU (carglumic acid)	BUPHENYL (sodium phenylbutyrate)	
	carglumic acid	
	OLPRUVA (sodium phenylbutyrate)	
	PHEBURANE (sodium phenylbutyrate)	
	RAVICTI (glycerol phenylbutyrate)	